(0-4 d), exposure to corticosteroids, or days of alcohol fixation (1-53 d). The alcohol fixed cases with the longest fixation times (41-53 d) showed variable degeneration of the RC. Immunostains for androgens stained Leydig cells, but not the RC. Conclusions: RC are very common, probably ubiquitous in normal testicles, but their number is variable. They show amphiphilic properties, dissolving rapidly in aqueous solutions (10% formalin). RC are not common in cytologic preparations from normal testes, and their presence suggests the presence of a LCT. Immunostains for androgens stain specifically the Leydig cells, but not RC.
Results: The study population was composed of predominantly females (75%) with a median age of 46.5 years. Distribution of the 8 benign GCTs tumors according to site was pharynx (n=1), tongue (n=1), esophagus (n=2), breast (n=1) and subcutaneous soft tissues (n=3). Both malignant GCTs occurred in subcutaneous soft tissue sites (flank and axilla). WES of patients with normal/tumor paired samples showed from 6 to 23 exonic mutations (4-16 non-synonymous), with no apparent difference in exonic mutation load between benign and malignant GCT. Mutated genes in benign GCT include PTCHD2, LAD1, PPP4R2, ZNF717, ORAI1, SETD1B, CENPJ, MYO5C, RABEP1, TRPM4, EIF4ENIF1, STARD8, and CENPI. Mutated genes in malignant GCT include INTS7, RAB1A, PIK3CA, TGFBI, MDN1, OPRM1, TP53, IRS4, SLC6A1, SWI5, MED13, and CILP2. Interestingly, only malignant GCT showed alterations in key known driver oncogenes such as TP53 and PIK3CA. In addition, both malignant but none of the benign GCTs had MUC3A gene copy number gains. Further analysis of indels, CNVs, and exonic translocations is ongoing. Conclusions: Identification of genetic alterations specific to GCT using WES even from archival FFPE material is feasible. These findings may provide the pathway for investigations aimed at determining the usefulness of a novel strategy for treating malignant PIK3CA-mutated GCT with targeted inhibitors (such as PI3K/AKT/mTOR inhibitors), either alone or in combination with other agents.
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Loss of p16 Expression and 18q23 Deletions as Potential Negative Prognostic Factors in Osteosarcoma
Dariusz Borys, Lukas Nystrom, Robert Canter, Andrew Horvai, Roger Schultz. Loyola University, Chicago, IL; University of California, San Francisco, CA; UCD, Sacramento, CA. Background: Osteosarcoma (OS) is a malignant primary tumor of bone affecting adolescent and young adults. There are few if any molecular markers to predict behavior and prognosis of OS.Our previous studies showed role of p16 as prognostic marker in OS. In the current study we used IHC for p16 and tumor necrosis studies to determine which other factors correlate with poorest chemotherapy response. Design: Genomic DNA was extracted from FFPE OS specimens obtained prior to initiation of chemotherapy. Microarray analysis was performed using a Roche® NimbleGen® array [OncoChip®(v2) ] with whole genome oligonucleotide coverage designed to reduce coverage in benign variable regions and enhance coverage in >2400 cancer features (i.e., genes known or suspected to be important in neoplasia). The microarray platform includes coverage of 67K SNPs with an average spacing of 40kb, affording the detection of genome-wide AOH, including copy-neutral events. p16 expression was determined by IHC staining. Results: Microarray results were obtained on 46/59 DNAs extracted from OS FFPE samples. Data on both p16 expression and pathologic tumor response to chemotherapy were available on 25/46 samples. Summarizing, deletion of RB1 (72%), gain of RUNX2 (68%), deletion of TP53 (52%), deletion 18q23 (48%) and p16-by IHC (28%) were common findings. Most abnormalities, particularly RB1 and TP53 deletion and RUNX2 gain did not correlate with chemotherapy response. IHC p16-status correlated strongly with failed chemotherapyresponse (6/10). Alterations of 18q correlated slightly with poor response (p=0.0796). Poor response cases included 3 cases with deletion of 18q23,3 cases with LOH for 18q23,1 case with copy gain (trisomy 18). Comparison of 18q genomic abnormalities in cases with a favorable versus poor response suggested a smallest region of overlap for a negative factor at 18q23 that includes the SALL3 [/ italic]gene.
Conclusions: We identified complex genotypes in the OS samples with frequent occurrence of previously identified biomarkers such as deletion RB1[/italic], deletion TP53[/italic], deletion 18q23 and gain of RUNX2[/italic].
Comparison of genomic findings to p16-status and chemotherapy response revealed p16-status to be the best overall indicator of a poor chemotherapy response, with the poorest responders being both p16-and altered for 18q23 including SALL3 gene. Additional studies are warranted to validate these findings and further characterize the role of CDKN2A [/italic] Background: Evaluation of resected post treatment osteosarcoma (OS) specimens is critical for therapeutic decision making and prognostic assessment. As per the Huvos grading system, ≥90% tumor necrosis (TN) following chemotherapy is considered a favorable response. Our study compared recurrence and survival rates between OS patients with ≥90% TN and <90% TN. Design: Patients diagnosed with high grade OS at Cohen Children's Medical Center from 1996 to 2011 were selected if they had undergone wide local resection after chemotherapy. Pathology reports and medical records were reviewed. Craniofacial osteosarcomas were excluded. This study was approved by the institutional IRB. Results: There were 23 subjects (52% male, 48% female, 44% African-American, 26% Caucasian, 30% Asian, Hispanic or other ethnicity). Age at diagnosis ranged from 4 to 29 years (mean = 14.61 +/-4.58 years, median = 15). Primary sites included distal femur (13 cases), proximal tibia (5 cases), proximal humerus (3 cases), distal ulna (1 case) and rib (1 case). Diagnoses included conventional OS (21 cases), telangiectatic OS (1 case), small cell OS (1 case). Nine patients died due to disease. The 1-year, 2-year, and 5-year survival rates were 90.91%, 86.36%, and 63.94%, respectively. Seven patients had either local or distant recurrence. The 1-year, 2-year, and 5-year progression free rates were 100%, 85.21%, and 67.70% respectively. The percentage chemotherapy-induced TN in the resection specimens ranged from 10% to 100% (mean: 63.61%, median: 70%). Six cases showed ≥90% TN. The median follow-up time was 7.14 years (95% CI: 6.3-9.2 years). There were no statistically significant differences between the high percentage TN group (≥90%) and low percentage TN group (<90%) with respect to overall survival, age at diagnosis, gender, ethnicity, tumor stage, and presence/ absence of metastasis at time of diagnosis. There was also no difference if the necrosis cut points were set at 70% or 80%. There was a significant association between age at diagnosis and time-to-recurrence (p<0.039; Hazard ratio=1.157: 95% CI: 1.008 to 1.328). For every year increase in age, the risk of recurrence increased by 16%. Conclusions: At our institution, post chemotherapy percentage TN did not correlate with overall survival or recurrence. Older subjects were at higher risk of recurrence than younger subjects. Jodi Carter, Robert Spinner, John Hawse, Caterina Giannini, Karen Fritchie. Mayo Clinic, Rochester, MN. Background: Neuromuscular choristoma (NMC) is a rare, malformative lesion composed of admixed nerve fibers and mature skeletal muscle, typically arising within the nerve fascicles of major nerve roots or trunks. Interestingly, desmoid-type fibromatosis often develops following biopsy or surgical intervention for NMC. To date, little is known about the pathogenesis of NMC or its association with fibromatosis (NMC-Fi). Desmoid-type fibromatosis is associated with CTNNB1 (beta-catenin) mutations, and the canonical Wnt signaling pathway, involving beta-catenin, has been implicated in development of the neuromuscular junction. Thus, we hypothesized that NMC and NMC-Fi may also harbor CTNBB1 mutations. In addition, desmoid-type fibromatosis expresses estrogen receptor beta (ER beta) and anti-estrogenic strategies are a therapeutic mainstay in unresectable cases. Therefore, we also characterized the ER isoform expression profile in NMC and NMC-Fi. Design: Cases of NMC with or without NMC-Fi were retrieved from our institutional archives. Clinico-radiologic and histologic features were re-evaluated to confirm the previous diagnoses. All NMC and NMC-Fi cases with available material underwent mutation analysis for CTNNB1 T41A, S45F and S45P by pyrosequencing. All cases were also tested for beta-catenin, ER alpha and ER beta protein expression using isoform-specific antibodies. Results: NMC occurred in 2 females and 3 males (mean age 14 years, range <1 to 51 y), as masses involving the sciatic nerve (N=4) or brachial plexus (N=1). In 4 of 5 cases, biopsy-confirmed NMC-Fi developed following biopsy or surgical intervention for the NMC. Three (of 5) (60%) NMC had CTNNB1 mutations (2:S45F; 1:T41A), including one case without NMC-Fi and two cases with subsequent NMC-Fi. In the latter group, the NMC-Fi had identical CTNNB1 mutations to those detected in the NMC. In 2 cases, CTNNB1 mutation was present in the NMC-Fi, but not in the original NMC. All NMC and NMC-Fi showed aberrant nuclear beta-catenin localization, strong and diffuse nuclear ER beta expression and lacked ER alpha expression. Conclusions: To our knowledge, we report for the first time that CTNNB1 mutations occur in NMC and NMC-Fi with high frequency. Furthermore, NMC and NMC-Fi express ER beta, and may respond to therapeutic estrogen antagonism.
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CTNNB1 Mutations and Estrogen Receptor Beta Expression in Neuromuscular Choristoma and Associated Fibromatosis
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Diagnostic Utility of Periostin To Distinguish Low Grade Chondrosarcoma From Enchondroma Shaoxiong Chen, Xianyin Lai. Indiana University, Indianapolis, IN. Background: Differentiation of low-grade chondrosarcoma from enchondroma can be very challenging histologically. To search for new protein biomarker candidates, a liquid chromatography -tandem mass spectrometry (LC-MS/MS) approach was carried out. One of top biomarker candidates, periostin, was identified and validated immunohistochemically. Periostin, also called osteoblast-specific factor 2, is an extracellular matrix protein and plays an important role in tumor progression in various types of cancer. Design: Formalin-fixed paraffin-embedded tissue blocks of low grade chondrosarcoma (5 cases) and enchondroma (5 cases) were obtained from the IU Health Pathology Laboratory and were used for protein extraction, respectively. Then protein reduction, alkylation, and digestion were performed using a previously published protocol. The digested protein specimens were analyzed using LC-MS/MS. Periostin immunostaining was performed in 23 low grade CHS and 31 enchondroma. The periostin immunostaining was scored according to staining extent (percentage of staining in the whole tumor tissue section; 0,<1%; 1+, 1-25%; 2+, 26-50%; 3+, 51-100%) and intensity (weak, moderate, or strong). Only extracellular matrix staining is considered to be positive. Results: Among the 23 low grade chondrosarcoma, 16 cases were positively stained (3+ in 2 cases, 1+ in 14 cases), while only 4 out of the 31 enchondroma tissue samples were positively stained (1+ in 4 cases). Among all positive staining cases, 90% (18/20) cases show strong focal staining (1+). Conclusions: Immunohistochemical staining of periostin in 23 low-grade chondrosarcoma and 31 enchondroma tissue specimens disclosed the specificity of 87% and the sensitivity of 70%. The main limitation of periostin staining is focal pattern, instead of diffuse pattern. Shaoxiong Chen, Shi Wei, Kristin Post, Kendra Curless, Eyas Hattab, Liang Cheng. Indiana University, Indianapolis, IN; University of Alabama, Birmingham, AL. Background: There is a growing trend to combine molecular testing with routine histologic examination for rendering a specific diagnosis. It has been reported in two previous studies that the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations are detected frequently (56% to 61%) in cartilaginous tumors but not in other mesenchymal tumors. In this study, we characterize the IDH1/2 mutations in conventional and dedifferentiated chondrosarcoma (CHS) collected at our institution. Design: A computerized search of the laboratory information system was performed for the 9-year period from 2005 through 2014 to identify CHS cases. Thirty cases (19 without decalcification and 11 with decalcification) were collected. The H&E slides from all cases were re-examined and diagnoses confirmed. DNA was extracted from formalin-fixed, paraffin-embedded tissues. IDH mutation analysis was performed using the Qiagen IDH1/2 RGQ PCR Kit, which detected mutations in codons 132 and 100 of the IDH1 gene and codon 172 of the IDH2 gene, respectively. Results: The age of the patients ranged from 27 to 95 years with a mean of 60. The male to female ratio was 1.5:1. The tumor size ranged from 2.5 cm to 47 cm. Among 19 specimens without decalcification, seventeen cases (13 conventional CHS and 4 dedifferentiated CHS) tested well for mutational analysis. One conventional CHS and one dedifferentiated CHS failed the test due to insufficient DNA quantity and unknown reason, respectively. All 11 conventional CHS with decalcification failed the test. A somatic mutation in either IDH1 or IDH2 was detected in 4 conventional CHS and 4 dedifferentiated CHS. Specifically, they were 2 R132H, 1R132C, and 1 R132 mutations in IDH1 gene and 4 R172 mutations in IDH2 gene. The remaining 9 cases showed wild type IDH1 and IDH2. Conclusions: Overall, 8/17 (47%) chondrosarcoma cases harbored a mutation in either IDH1 or IDH2 genes. DNA extracted from decalcified specimens is not suitable for mutational analysis due to severe damage by hydrochloric acid. Identification of IDH1/IDH 2 mutations may be useful in confirming the diagnosis of chondrosarcoma, especially among dedifferentiated examples.
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IDH1/2 Mutational Testing for the Diagnosis of Conventional and Dedifferentiated Chondrosarcoma
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Prevalence of MiTF and Other Melanocytic Markers in Undifferentiated Pleomorphic Sarcoma: Caution Is Advised Bonnie Choy, Peter Pytel, Rex Haydon, Anthony Montag, Nicole Cipriani. University of Chicago Medicine, Chicago, IL. Background: Undifferentiated pleomorphic sarcoma (UPS) is a soft tissue sarcoma that does not demonstrate a specific lineage of differentiation. Diagnosis of UPS may be challenging, as other lesions with undifferentiated spindle cell morphology must first be excluded, including melanoma. Microphthalmia-associated transcription factor (MiTF), a DNA-binding protein that plays a role in melanocyte development, was originally reported as a highly specific nuclear marker for benign cutaneous nevi and epithelioid melanoma. A later study reported MiTF expression in a number of spindle cell lesions, including fibrous histiocytoma and fibrosarcoma. Our aim was to evaluate the prevalence of MiTF and other melanocytic markers (SOX10, Melan-A, HMB45, and S100) in UPS. Design: MiTF, SOX10, Melan-A, HMB45, and S100 immunohistochemical stains were performed on formalin-fixed paraffin-embedded resection specimens from 19 adult patients (age 41-83) with UPS of the deep soft tissue of the extremities or trunk. Neoadjuvant chemo-or radiotherapy was given in 5 patients. No patient had a known history of melanoma. Results: In 17 of 19 UPS (89%), tumor cells showed nuclear positivity for MiTF, ranging from very focal to diffuse. 4 cases had been previously treated. In 3 cases (all MiTF-positive, 1 previously treated), focal nuclear staining for HMB45 was seen. In 1 case (MiTF-positive, untreated), focal nuclear staining for S100 was seen.None of the UPS showed expression of SOX10 or Melan-A. Conclusions: There is a high prevalence (89%) of nuclear MiTF expression in UPS. Additionally, 16% and 5% of cases showed nuclear HMB45 and S100 staining, respectively. This finding urges against using MiTF in isolation to differentiate between UPS and melanoma, as well as caution in using focal staining for a single additional melanocytic marker. MiTF may be used to support a diagnosis of melanoma only if multiple other melanocytic markers are positive.
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Molecular Detection of Solitary Fibrous Tumors Shows Distinctive Site-and Age-Related Variability in NAB2-STAT6 Fusion Types: Clincopathological, Immunohistochemical, and Genetic Analysis in 90 Cases I-Chieh Chuang, Tse-Ching Chen, Hui-Chun Tai, Shih-Chiang Huang, Chien-Feng Li, Yu-Chien Kao, Jen-Wei Tsai, Hsuan-Ying Huang. Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung Memorial Hospital, Taoyuan, Taiwan; Changhua Christian Hospital, Changhua, Taiwan; Chi Mei Medical Center, Tainan, Taiwan; Wan Fang Hospital, Taipei, Taiwan; E-Da Hospital, Kaohsiung, Taiwan. Background: Solitary fibrous tumor (SFT) harbors the NAB2-STAT6 gene fusion with complex exon composition but consistent STAT6 nuclear expression. Previously, RT-PCR was performed mainly on fresh tissues, since FISH is technically demanding to detect the two rearranged, juxtaposed genes. Design: We investigated the associations between clinicopathological features and this pathogonomic hallmark by analyzing STAT6 immunostain in 28 intrathoracic, 38 extrathoracic, and 24 meningeal SFTs, histologically classified as 1 dedifferentiated, 13 malignant, 12 atypical, and 64 typical cases. RT-PCR was performed on assessable RNAs from 80 formalin-fixed and 2 fresh samples. Results: RT-PCRrevealed 11 exon composition types of NAB2-STAT6 fusion in 74 cases and negative results in 8. Among 3 common types collectively accounting for 86.5% of fusion-positive cases, NAB2ex6-STAT6ex16 (n=16) exhibited highly variable breakpoints and occasional incorporation with sequences of NAB2 and/or STAT6 introns, unlike the predominant NAB2ex4-STAT6ex2 (n=33) and nearly frequent NAB2ex6-STAT6ex17 (n=15). Being diffuse and intense in 86(95.6%) cases, STAT6 nuclear immunoexpression was observed in 89(98.9%) SFTs, including all 74 fusion-positive tumors, with focal cytoplasmic staining in few histological mimics. Notably, 7 of 8 fusion-negative cases still exhibited STAT6 nuclear expression, suggesting rare fusion variants beyond the detection by RT-PCR.Regardless of histological classification, the NAB2ex4-STAT6ex2 was related to older age (p=0.007) and preferentially occurred in the intrathoracic SFTs, compared with the meningeal (p<0.001) or extrathoracic counterparts (p=0.003) that more frequently harbor NAB2ex6-STAT6ex16, NAB2ex6-STAT6ex17, or other miscellaneous variants. Conclusions: Most SFTs strongly and diffusely express STAT6 in the nuclei, representing a robust diagnostics and corresponding to 90.2% of cases detectable for NAB2-STAT6 transcripts. The determination of NAB2-STAT6 fusion variants may be clinically and biological relevant, given the site-and age-dependent differences in the preponderant fusion variants.
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MDM2 Amplification in Problematic Lipomatous Tumors: Analysis of FISH Testing Criteria
Michael Clay, Anthony Martinez, Sharon Weiss, Mark Edgar. Emory University Hospital, Atlanta, GA. Background: To differentiate lipoma and its variants (L/V) from well-differentiated liposarcoma (ALN/WDL), we perform fluorescent in-situ hybridization (FISH) for MDM2 amplification in the following situations: 1. Deep "lipomas" that are greater than 10 cm, 2. Superficial or deep" lipomas" with an ambiguous level of atypia or atypia of uncertain significance, 3. Recurrent deep "lipomas," and 4. All retroperitoneal/ abdominal "lipomas". We have analyzed our experience to determine the situations in which testing is most informative. Design: All differentiated lipomatous tumors on which FISH for MDM2 amplification was performed using above criteria since 2010 were reviewed (n=298; consultation cases= 226; institutional cases =72). Final classification was based on the MDM2 amplification status. No cases were included if the diagnosis could be made on the basis of the hematoxylin-eosin slides. Statistical analysis was performed in each category. Results: FISH was most often performed for "lipomas" greater than 10 cm (n=126), followed by superficial or deep lesions with equivocal atypia (n=96; 44 superficial, 52 deep), retroperitoneal "lipoma" (n=63), and recurrent deep lipomas (n=32). Of the deep tumors >10 cm, 56 tumors proved to be ALN/WDL, and 70 L/V; the two did not differ statistically in size (p=0.58). For lesions with equivocal atypia, 52 lesions were deep (21 ALN/WDL, 31 L/V), and 44 lesions were superficial (1 ALN/WDL; 43 L/V). Among recurrent deep "lipomas," ALN/WDL (n=17) and L/V (n=15) were represented nearly equally, but among retroperitoneal tumors L/V (n=40) were represented more frequently than ALN/WDL (n=23). No ALN/WDL occurred in superficial/deep tissues of the hands and feet. Overall, testing identified 118 ALN/WDLs (40% of cases tested). Conclusions: FISH for MDM2 amplification is invaluable for deep lesions that are >10 cm, recurrent or have ambiguous atypia as well as for abdominal/retroperitoneal lesions, as it identifies a significant subset of patients that would otherwise be considered to have lipomas and would receive different therapy. Testing is less valuable for superficial lesions with ambiguous atypia because they rarely prove to be ALN/WDL and would not require therapy beyond conservative excision given their location. The unexpectedly high percentage of lipomas among retroperitoneal lesions probably reflects both the bias of our consultation practice and refinement of our diagnostic accuracy.
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SATB2 Expression Is Sensitive But Not Specific for Osteosarcoma Compared To Other High-Grade Primary Bone Sarcomas
Jessica Davis, Andrew Horvai. University of California, San Francisco, CA. Background: Osteosarcoma (OS) is defined by the presence of osteoid or bone production by malignant cells. However, osteoid can be focal. Thus not all biopsies demonstrate this diagnostic feature making the distinction between OS and other poorly differentiated bone tumors, including fibrosarcoma (FS) and undifferentiated pleomorphic sarcoma (UPS) is challenging. Yet, treatment and enrollment in clinical trials depends on accurate pathologic diagnosis. The special AT-rich sequence-binding protein 2 (SATB2) is a nuclear matrix protein that regulates osteoblast differentiation. SATB2 shows promise as a diagnostic adjunct for OS insofar as SATB2 immunostaining is highly sensitive for osteoblasts. However, the specificity of SATB2 to discriminate OS from other high-grade bone sarcomas, where SATB2 might be most useful, is not well characterized. This study sought to determine if SATB2 can distinguish OS from other bone sarcomas, even when osteoid is absent on a biopsy. Design: Forty bone biopsies of high-grade sarcomas lacking tumor-produced osteoid or bone were identified in departmental archives. Seven tumors could be classified as OS because osteoid production by viable malignant cells was present on resection specimens. The remaining 33 tumors (22 UPS and 11 FS) lacked osteoid production on the biopsies and on subsequent resection specimens and lacked definitive radiographic features of OS. Clinicopathologic features were recorded. Using standard immunohistochemistry on whole sections, SATB2 nuclear expression was measured for staining extent (0, no staining; 1+, <5%; 2+, 5-25%; 3+, 26-50%; 4+, 51-75%; 5+, 76-100%) and intensity (weak, moderate, strong). Results: All OS (7/7, 100%) were positive for SATB2 and 4/7 (57%) showed strong staining. SATB2 was positive in 11/22 (50%) UPS and 5/11 (45%) FS. Together, 8/33 (24%) non-OS tumors displayed strong staining. Sensitivity and specificity of SATB2 for OS were 100% and 51%, respectively. Tissue decalcification status, patient age and gender did not correlate with SATB2 staining (p>0. 99, p=0.19 and p >0.99, respectively Conclusions: These results support that SATB2 is a highly sensitive marker OS even in the absence of osteoid. However, a positive SATB2 result lacks sufficient specificity to reliably distinguish OS from other high grade bone sarcomas. 1 We investigated the frequency of several common and uncommon fusion variants in a subset of SFT with clinicopathologic correlation. Design: RNA was extracted from 31 formalin-fixed, paraffin embedded (FFPE) primary pleural SFTs and subjected to multiplexed QRT-PCR for 3 of the most frequently reported fusion transcript types (NAB2-STAT6 exons 4-2; 6-16; and 6-17, as well as 7-2, an unusual fusion variant), using previously published primer sequences.
1 Results were correlated with STAT6 immunohistochemistry, clinicopathologic features and patient outcomes. Results: All 31 cases were strongly positive for nuclear STAT6 (C-terminal) by immunohistochemistry. QRT-PCR was successful in 29 cases. 17/29 (59%) cases had a 4-2 fusion type in multiplexed reactions. Twelve cases were negative for all 4 tested fusion types. Tumors with 4-2 fusion trended to be larger at diagnosis (median 9 cm (range 3.0-23.0 cm)) than cases with unknown fusion ((median 5 cm (1.0-12.4 cm)) (p=0.072).There were no statistically significant differences in patient age, mitotic activity, race, or sex between cases with 4-2 fusion type and cases with unknown fusion type. Using our previously published risk stratification system, 2 only 29% of patients with 4-2 fusion type would be considered low-risk of metastasis in contrast to 83% of patients with unknown-fusion variants (p=0.004). Clinical follow-up was available in 17 cases (12 with 4-2 fusion type, and 5 unknown fusion), and ranged from < 1 month to 13 years (median 44 months). One patient with 4-2 fusion developed metastases at 37 months, while 16 patients were disease-free at last follow-up. Conclusions: Our findings confirm a relatively high frequency of the 4-2 NAB2-STAT6 fusion type in pleural SFT. However, a higher proportion of our cases than expected were negative for this type, likely due to differences in patient population. Testing is underway on an additional 175 cases of pleural, meningeal and soft tissue SFT. Background: Over the years I have observed in consultation subcutaneous fatty tumors that exhibit notable variation in fat cell size but not more than slight nuclear enlargement and atypia. Being uncertain of their proper classification and behavior, I decided to undertake a review. Design: Consultation cases in our files diagnosed before 2008 and described in the reports as showing the abovementioned features were reviewed. Inclusion criteria were that there be adequate pathologic material demonstrating the appropriate histologic characteristics and at least some follow-up information. Results: The study group consisted of 12 men and 1 woman aged 36 to 79 yrs (median 57 yrs). The most common tumor locations were the neck and back (3 each; 1 man had 2 separate tumors involving the neck and back). Other sites included the chest wall (2), breast (1-the woman), breast and axilla (1-a man), arm (1), shoulder (1), scrotum (1), and pubic area (1). All the tumors were subcutaneous. Excision (sometimes in fragments) was the initial treatment in all cases. This was followed by re-excision in 3 cases (shoulder, breast, and scrotum), with all re-excision specimens being negative for tumor. Tumor size (which was estimated from aggregate or largest fragment dimensions in the instances of fragmented specimens) ranged from 4.1 to 9.1 cm (median 6 cm).
Histologically, all the tumors demonstrated variable fat cell size, sometimes strikingly so. In contrast to this, nuclear enlargement and atypia ranged from inapparent to slight. Microscopic foci of fat necrosis, which varied from occasional to plentiful, were a consistent finding. Some tumors had an intermixed fibrous or fibromyxoid component, but this never dominated and always lacked nuclear atypia (which was instead confined to fat cells). On follow-up of 4 to 11 yrs (median 9 yrs), 10 patients had no recurrence of the tumor. 2 had local recurrences excised, 1 at 6 yrs (neck) and 1 at 9 mos (the patient with neck and back tumors, both of which recurred); additional follow-up could not be obtained on either patient. A third patient (breast and axilla) had a local recurrence that had not been excised at the latest follow-up of 9 yrs. Conclusions: The tumors reported on here form a group distinct from both atypical lipomatous tumors and ordinary lipomas by virtue of their combination of preponderant occurrence in men, exclusively subcutaneous location, significant variability of fat cell size coupled with unnoticeable to minor nuclear atypia, and appreciable but relatively low rate of local recurrence.
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Frequency and Clinicopathologic Profile of PIK3CA Mutant GISTs Anna Felisiak-Golabek, Bartosz Wasag, Tiffany Coates, Jerzy P Lasota, Markku Miettinen. National Cancer Institute, Bethesda, MD; Medical University, Gdansk, Poland. Background: GIST, the most common mesenchymal tumors of GI tract is driven by oncogenic activation of receptor tyrosine kinases, KIT or PDGFRA. Recently, gainof-function mutations in PIK3CA, a gene that encodes the 110α cathalytic subunit of PI3K, were reported in GIST. Previously, mutational activation of PI3K/AKT signaling pathway has been identified in human cancer. In GIST, PIK3CA mutations were found in 2 gastric tumors (in one concurrent to KIT mutation) and in treatment resistant metastatic lesion of BRAF-mutant GIST. It seems that mutational activation of PI3K/AKT signaling pathway may play a role in both GIST pathogenesis and tumor progression. The aim of this study was to define frequency of PIK3CA and AKT1 mutations in imatinib-naïve GISTs. Design: Cohort of well characterized, CD117 and DOG1 positive GISTs was evaluated for PIK3CA exon 9 and 20 and c.49G>A (p.E17K) AKT1 mutation. DNA was extracted from FFPE tumor samples. PIK3CA exon 20 and AKT1 exon 3 PCR amplification products were analyzed by Sanger sequencing, while PIK3CA exon 9 were evaluated by high resolution melting analysis. Results: Seven PIK3CA mutations were identified in 6 of 415 (1.5%) analyzed GISTs, although they account for 2.5% of malignant tumors. Following substitutions were identified: c.3140A>G, c.3140A>T, c.3103G>A, c.3127A>G, c.3137C>T, c.3143A>G, c.3158C>T. At the protein level, these substitutions would lead to p.A1035T, p.M1043V, p.A1046V, p.H1047R, p.H1047L, p.H1048R, p.T1053I mutations, respectively. In one tumor two substitutions c.3103G>A and c.3158C>T were detected. Three PIK3CA mutants were previously evaluated for KIT, PDGFRA, BRAF and RAS mutations and turned to be KIT exon 11 mutants. There were 2 gastric and 4 retroperitoneal tumors. These 6 patients included 3 men and 3 female (mean age, 51 years). Five tumors were > 10cm with the mitotic activity 3 to 72 mitosis/50HPF. The follow-up showed short, < 35 months, survival (n=5). No PIK3CA exon 9 or AKT1 mutants were identified in 100 GISTs analyzed. Conclusions: PIK3CA mutations were identified in a subset of imatinib-naïve, highly advance, malignant GISTs. This could suggest that PIK3CA mutant clones may have proliferative advantage over other clones without the pressure imposed by targeted therapies. Because presence of PIK3CA mutation may have significant implications on the selection of the targeted therapy, screening for such mutations should be considered in primary highly advance and metastatic GISTs.
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Composite Hemangioendothelioma: A Clinicopathologic Study of Nine Cases Masaharu Fukunaga. Jikei University Daisan Hospital, Tokyo, Japan. Background: Composite hemangioendothelioma (HE) is a low-grade malignant vascular tumor showing varying combinations of benign, low-grade malignant, and malignant vascular components. The predominant histologic components are histologically identical to epithelioid HE and retiform HE. There have been only 28 cases of composite HE reported in the English literature, and its nature and biological behavior remain unknown. Design: The clinicopathologic and immunohistochemical features of nine cases of composite HE including a case with associated Maffucci syndrome are described. Results: The patients were seven females and two males with a median age of 36.0 years (range, 8-75 years). All tumors occurred in the dermis and/or subcutis. The tumors arose in the foot or lower leg in 6 patients, in the face in two patients, and as multiple tumors in the left upper extremity in one patient. Two patients had congenital tumors, in the lower thigh and foot, or upper extremity. The lesions were usually of several years duration. The size of individual tumors ranged from 1.0 to 30 cm. The tumors were composed of a complex admixture of histologic components resembling various vascular lesions. The predominant components, present in all cases, resembled retiform HE and epithelioid HE. Angiosarcoma-like areas were observed in three cases. Lymphangiomalike areas were found in two cases. Areas of spindle cell hemangioma, cavernous hemangioma or arteriovenous malformation were identified in two cases each. The two congenital cases exhibiting multiple lesions had angiosarcoma-like components and an angiomatosis-like growth pattern. One patient each was associated with KasabachMerritt or Maffucci syndrome. Immunohistochemically, all tumors showed expression of at least two endothelial markers (CD31, CD34, factor VIII-related antigen and/or D2-40). Of eight cases that were followed up (median duration, 8.2 years), one tumor recurred locally. One was a recent case. To date, none of the patients have developed metastases. There was no difference in biologic behavior among cases with various combinations of histology in this study.
Conclusions:
The findings expand the clinical and histologic spectrum of this tumor. There was no difference in biologic behavior among cases showing various combinations of histology in this study and previously reported cases. Composite HE should continue to be regarded as a low-grade malignant vascular tumor (hemangioendothelioma), with significant potential for local recurrence, but little if any potential for distant metastasis. Rondell Graham, Michael Torbenson, Alaa Salim, Long Jin, Margaret Chou, Andre Oliveira, David Stockman. Mayo Clinic, Rochester, MN; University of Texas MD Anderson Cancer Center, Houston, TX; Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA; University of South Carolina School of Medicine, Greenville, SC. Background: The presentation of Ewing sarcoma(ES) in the gastrointestinal(GI) tract is rare and can be confused with other tumors bearing overlapping histologic features. Design: Tumors with diagnoses of ES involving the GI tract were retrieved from the institutional archives from 1991 to 2014. The diagnosis of ES was confirmed by histologic review together with immunohistochemistry and molecular testing on paraffin embedded sections. Tumors were assessed by fluorescence in situ hybridization (FISH) for rearrangement of EWSR1 locus and RT-PCR for EWSR1-FLI1 and EWSR1-ERG fusion transcripts. A control group of 20 randomly selected cases of ES of bone were selected for comparison. Results: Ewing sarcoma(n=28) occurred in 17M/11F(median 35 yrs, range 3-79) and varied in size from 3.5-17.0 cm(median 8.5). Tumors involved the small intestine(n=9), colon(n=7), pancreas(n=7) and stomach(n=5). In 13 cases, tumor extension into the mesentery and omentum was noted. Original referring diagnoses included desmoplastic small round cell tumor and lymphoma. In 8 cases, the patients presented with metastases to liver, lung and/or regional lymph nodes. Tumors featured highly cellular sheets of small round cells which expressed CD99(100%), FLI1(75%), chromogranin(15%), and synaptophysin(39%). Desmin, CD117, and S-100 protein were negative in all cases. Rearrangement of EWSR1 locus by FISH was present in 16/16 cases, with EWSR1-FLI1 in 9/14 cases(64%) and EWSR1-erg in 3/14(21%) cases; no fusion transcript was identified in 2 cases, consistent with alternate fusions. Nine patients died of disease after 3 to 85mo(median, 23mo); 8 patients were alive with disease and 2 without evidence of disease(median, 7mo). Metastases developed in 17 patients after periods of up to 81mo. ES of the GI tract had inferior five-year survival rates(27%) when compared to osseous ES(56%). Conclusions: Primary ES of the GI tract is rare and can be distinguished from other small round cell tumors by careful integration of histologic and molecular data. When compared to historical controls of osseous ES, primary ES of the GI tract appears to present at a more advanced age and follow a more aggressive clinical course.
Primary Ewing Sarcoma of the Gastrointestinal Tract: A Clinicopathologic and Molecular Study of 28 Cases
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Next-Generation Sequencing of Follicular Dendritic Cell Sarcomas Reveals Recurrent Alterations in the Retinoblastoma and Hedgehog Signaling Pathways
Background: Follicular dendritic cell (FDC) sarcoma is a rare mesenchymal neoplasm that usually arises at lymphoid tissue-rich sites. Extranodal tumors often pursue an aggressive clinical course; however, effective systemic therapies are lacking. The genetic basis for FDC sarcoma is unknown. The purpose of this study was to search for recurrent genomic alterations in FDC sarcoma by next-generation sequencing (NGS). Design: DNA was extracted from formalin-fixed paraffin-embedded tissue sections from 7 cases of FDC sarcoma (6 M, 1 F; age range: 22-60 yrs; 2 neck lymph nodes, 2 abdominal cavity, 1 tonsil, 1 liver, 1 chest wall). Samples were analyzed by targeted exon hybrid capture (Agilent) and NGS using the Illumina HiSeq 2500, interrogating exonic sequences of 300 cancer-associated genes for mutations and copy number variants (CNV), as well as 113 introns across 35 genes for rearrangements. Mutation calls were generated using MuTect and GATK, copy number calls using VisCap Cancer, and large structural variants using BreakMer. Based on the NGS results, immunohistochemistry (IHC) for RB1 was performed. Results: CNV were uninterpretable in 2 samples due to poor coverage. All 5 other samples showed frequent genetic losses across multiple chromosomes and a lack of amplification events, suggestive of tumor suppressor gene-driven biology. CDKN2A deletions were observed in 3 of 5 (60%) tumors (2 homozygous; 1 with 1-2 copy deletion), and 3 of 5 (60%) showed RB1 alterations (1 homozygous deletion; 1 truncating mutation; 1 heterozygous deletion accompanied by RBL2 heterozygous deletion). Loss of RB1 expression in the former 2 cases was confirmed by IHC. Homozygous deletion of CYLD was identified in 2 of 5 (40%) cases, both with RB pathway alterations. Of note, no BRAF mutations were identified. Conclusions: FDC sarcoma harbors recurrent alterations in the retinoblastoma (RB1, CDKN2A) and hedgehog (CYLD) signaling pathways. These pathways have been shown to cooperate in the tumorigenesis of other types of malignant neoplasms, including retinoblastoma and small cell carcinoma. Loss of CYLD suggests possible opportunities for targeted therapy (currently in clinical trials for other tumor types), at least in a subset of cases.
ERG Expression in Low Grade Hyaline Cartilage Neoplasms: A Potential Diagnostic Tool in the Evaluation of Enchondromas and LowGrade Chondrosarcomas
Sounak Gupta, Wonwoo Shon, Karen Fritchie. Mayo Clinic, Rochester, MN; University of Florida College of Medicine, Gainesville, FL. Background: Enchondromas are benign cartilaginous neoplasms which rarely recur and can be managed conservatively. In contrast, low grade chondrosarcomas are locally aggressive tumors with potential for recurrence and rare metastasis. Despite differences in clinical behavior, distinguishing enchondroma from low grade chondrosarcoma on morphologic features alone is extremely difficult with high interobserver variability. Experimental studies have shown that the ets transcription factor ERG is involved in cartilage tissue development and maintenance of chondrocytes in a differentiated state. ERG has also been reported to be preferentially expressed in embryonic and growth plate cartilage. Prompted by our recent finding of ERG protein expression in selected chondrogenic mesenchymal tumors, we sought to explore the utility of ERG as an immunohistochemical marker in differentiating enchondromas from low grade chondrosarcomas. Design: A total of 29 enchondromas (14 involving small bones of the hands and feet and 15 affecting long bones) and 16 cases of axial low grade (grade 1 (of 3)) chondrosarcomas (skull base, vertebral body, rib, sternum, pelvis) were retrieved from the Mayo Clinic surgical pathology archives. Clinical and radiologic findings were reviewed and correlated with histologic features to confirm the diagnoses. A representative tissue block from each case was selected and immunostained with anti-ERG monoclonal antibody to the N-terminus (9FY, 1:50-1:100, BioCare). Nuclear localized ERG expression was graded as 0 (no staining), 1+ (<5%), 2+ (5-50%) and 3+ (>50%). Cases with 2+ or 3+ scores were considered positive. ERG expression in vascular endothelial cells was utilized as a positive internal control. Results: All but 1 enchondroma (28/29, 97%) were negative for ERG expression (0 or 1+), while 69% (11/16) of low grade chondrosarcomas were positive for ERG (2+ or 3+) with 6 cases showing 2+ staining and 5 cases showing 3+ staining. Conclusions: ERG seems to be preferentially expressed in low grade chondrosarcomas compared to enchondromas (p<0.05) and may be a potential diagnostic aid in the histopathologic classification of low grade hyaline cartilage neoplasms.
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Mammar y-Type Myofibroblastoma: Clinicopathologic Characterization in a Series of 140 Cases Brooke Howitt, Christopher Fletcher. Brigham & Women's Hospital and Harvard Medical School, Boston, MA. Background: Mammary-type myofibroblastoma (MTMF) is an uncommon benign neoplasm initially described in the breast; however, it is now recognized to occur in a wider anatomic distribution. MTMF is associated with cytogenetic abnormalities in 13q, and frequently shows loss of Rb by immunohistochemistry (IHC). Design: Archival cases were retrieved and the diagnosis of MTMF was confirmed. Hematoxylin and eosin (H&E) stained slides and IHC stained slides were reviewed when available (CD34, desmin, and Rb). Patient age, gender, anatomic location of tumor, type and duration of preceding symptoms, tumor size, and type of sampling (biopsy vs excision) was recorded. For excisions, margin status was recorded when possible. Clinical data were requested for recurrent tumor, metastasis, and patient status at last followup. Results: 140 cases of MTMF comprised this study, consisting of 92 (66%) males and 48 (34%) females with a mean age of 54.5 years (range 4-96 years). The mean tumor size was 6.9 cm (range 1-22 cm). Anatomic location included breast (14; 10%), chest wall/axilla (8; 6%), inguinal/groin/vulva/scrotal/paratesticular (61; 44%), trunk (19; 14%), extremities (18, 13% lower; 2, 1% upper), head/neck (3; 2%), vaginal (2; 1%), or visceral (mostly retroperitoneal or pelvic, 13; 9%). Most cases showed typical morphologic features of MTMF. Cytologic atypia or epithelioid morphology was present in 10 (7%) and 6 (2%) cases, respectively. CD34 and desmin were positive in 90% and 89%, respectively. Both CD34 and desmin were negative in 3%. Rb was lost by IHC in 57/62 (92%) with 17 cases showing only a subset of tumor cells losing Rb expression. Rb was intact in 2 (3%) and equivocal in 3 (5%). No cases with followup data available thus far (n=31) had tumor recurrence (mean 15.5 months, median 11 months). Conclusions: Even when allowing for consult bias, MTMF appear to be more common at extra-mammary sites than in the breast, and can cause diagnostic difficulty when atypia or epithelioid morphology is present, or when located at an unusual anatomic site. Immunophenotypically, MTMF usually shows loss of Rb expression (92%), and is frequently positive for CD34 and desmin; however rare cases (3%) are negative for both. Recurrence seems to be rare, even in the presence of positive resection margins. Shih-Chiang Huang, Hsiao-Wei Chen, Lei Zhang, Yun-Shao Sung, Brendan Dickson, Thomas Krausz, Christopher Fletcher, Cristina Design: We applied next generation paired-end RNA sequencing and FusionSeq algorithm to a typical EH occurring in the rib of a 45 year-old man. A novel LMNA-FOS gene fusion was identified, which was then confirmed by reverse transcription polymerase chain reaction and fluorescence in situ hybridization. Break-apart FOS probes were then used to screen 34 cases of EH without FOSB alterations. The clinical and pathological features of FOS-rearranged EH were investigated. Results: There were 14 cases (41%) with FOS gene rearrangements, including 10 males and 4 females, with a mean age of 45 years (range 15-67). Most of the FOS-rearranged EH were intra-osseous (7/14, 50%) and soft tissue (5/14, 36%), while 2 occurred in the skin. The predominant anatomic site affected was within extremities (10/14, 71%), with rare examples in the head and neck, trunk and penis. Histologically, all tumors were composed of an intimate mixture of lumen-forming vascular structures and strands of epithelioid endothelial cells, with variable amount of inflammatory infiltrate. Three cases had increased cellularity with solid growth pattern and focal spindling. Only one case demonstrated moderate nuclear pleomorphism and increased mitotic activity (5/10 HPF). Conclusions: FOS rearrangement was present in 41% of EHs with classic morphology and emerges as the most frequent genetic abnormality in this disease, which can be used as a reliable molecular marker in the work-up of challenging epithelioid vascular tumors. The oncogenic activation of FOS and FOSB, members of the Fos gene family that dimerize with JUN proteins forming the transcription factor complex AP-1, is emerging as a key event in the tumorigenesis of benign and intermediate groups of vascular tumors. Background: Myoepithelial (ME) tumors of soft tissue and bone have diverse morphologic appearances and genetic alterations, with about half harbouring EWSR1 gene rearrangements. Although documented as isolated case reports, the prevalence of FUS gene abnormalities and any related fusion partners remains undetermined among the ME spectrum. Design: Fluorescence in situ hybridization (FISH) was used to screen 62 EWSR1-negative soft tissue, bone and visceral ME tumors for FUS abnormalities. In an index FUS-rearranged case with available frozen tissue, 3'-Rapid Amplification of cDNA Ends (RACE) was applied to identify the fusion partner. Results were further confirmed by RT-PCR, followed by FISH screening the entire cohort of FUS-rearranged cases. As the fusion partner proved to be a recurrent event, 16 additional bone and soft tissue EWSR1-positive ME lesions lacking a known fusion partner were tested for this abnormality. The correlation between genotype and clinicopathologic features was also investigated. Results: Five (8.1%) FUS-rearranged cases were identified, spanning divergent age groups, tumor locations, morphological characteristics and behavior. A novel FUS-KLF17 fusion was identified by 3'RACE in an 11 year-old girl with a foot lesion, metastatic to ipsilateral thigh. Two additional cases with FUS-KLF17 fusions were identified in the lung of a 30 year-old man and tibial periosteum of an 8 year-old boy. Additionally, one KLF17 rearrangement (6.3%) was found in a foot soft tissue lesion among the 16 EWSR1-positive ME tumors. The KLF17-rearranged ME tumors had a predilection for children and exhibited trabecular growth in a myxohyaline stroma, but did not correlate with a malignant phenotype. KLF17 (Krueppel-like factor 17), a member of KLF transcription factor family, has not been previously implicated in gene fusions, but was shown to regulate epithelial-mesenchymal transition and metastasis in other cancers. Conclusions: This is the largest series assessing FUS gene abnormalities in a broad spectrum of ME lesions. A small subset of ME tumors harbor FUS rearrangements, most of them (60%) being associated with KLF17 fusion. FUS FISH analysis is recommended in EWSR1-negative lesions in which a ME diagnosis is suspected. KLF17 is also a rare gene fusion partner to EWSR1 in ME tumors.
Frequent FOS Gene Rearrangements in Epithelioid Hemangioma
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Diagnostic and Prognostic Value of CTNNB1 Mutation Testing in Sporadic Fibromatosis
Soo Hyun Hwang, Taeeun Kim, Boram Lee, Yoon-La Choi. Samsung Medical Center, Seoul, Republic of Korea. Background: Fibromatoses are benign fibroblastic or myofibroblastic tumors that are locally aggressive and recur frequently. Although no reliable markers for tumor recurrence risk have been identified, point mutations in the CTNNB1 gene are consistently observed in sporadic fibromatoses. The aim of this study was to investigate the frequencies of CTNNB1 genotypes in these tumors and to correlate specific genotypes with clinicopathologic parameters, including propensity for recurrence. Design: The tumor population included 95 desmoid-type fibromatoses. CTNNB1 genotyping was performed on all 95 tumors and β-catenin immunohistochemical staining was performed on tissue microarray blocks. We analyzed relationships between recurrence and variables such as CTNNB1 mutation, β-catenin immunostaining, and clinical parameters. Results: CTNNB1 mutations were found in 71/95 tumors (75%). Of these, an ACC to GCC transition in codon 41 (T41A) was identified in 40 cases (42%), TCT to TTT in codon 45 (S45F) was identified in 27 cases (28%), and TCT to CCT in codon 45 (S45P) was identified in 4 cases (4%). Nuclear β-catenin expression was found in 82/94 tumors (87%). In the follow-up of 91 patients, 31/91 patients (34%) developed tumor progression. On multivariate analysis in desmoid tumors, age younger than 30 years and tumor size ≥ 10cm were significantly associated with tumor recurrence (age: p=0.026, odds ratio 0.320 , 95% CI 0.117-0.875; and size: p =0.017, odds ratio 5.467, 95% CI 1.361-21.965). The other variables, including gender, tumor location, CTNNB1 mutation, margin status and immunostaining for β-catenin, were not significantly associated with recurrence. Conclusions: CTNNB1 mutation testing may potentially be used to improve the accuracy of diagnosis but not be demonstrated tumor recurrence alone in sporadic fibromatoses. Background: Polypropylene meshes, introduced in the late 50's, are presently used in millions of surgeries worldwide. Up to 10% are excised for complications or recurrence generating a large, but underutilized body of study material. Paradoxically, most conclusions of mesh-body interactions are based on animal studies while countless specimens pass through pathology departments. Design: 32 excised hernia meshes from 12 female and 20 male patients with age range 24-82years were reviewed. Of 13 ventral hernias 2 were removed for migration into the urinary bladder and fallopian tube, 4 for infection and 7 for recurrence. Of 19 groin meshes 7 were excised for pain and 12 for recurrence. The following parameters were scored independently by two pathologists: mesh deformation, extent of fibrous encapsulation, nerve density and ingrowth, degree of inflammation, edema, vascular thrombosis, fat necrosis, muscle involvement, polypropylene degradation. Results: All meshes showed folds and scar encapsulation bridging >90% of mesh pores. Density of nerve branches ingrown into the meshes was higher in the specimens excised for pain (p<0.001). Involvement of striated muscle showed less pronounced, but significant association with pain (p=0.05). Meshes removed for pain also showed trends of more pronounced foreign body reaction and edema in the scar inhabiting the mesh. The amount of scarring with bridging fibrosis and the degree of foreign body reaction tended to be reduced over time, but appeared patient dependent. Polypropylene material showed a degradation layer forming a sheath around the filaments. The layer was detectable by its ability to trap dyes, however it retained birefringence of polypropylene in polarized light. Conclusions: Tissue ingrown into the mesh is innervated and exposed to all regular pain mechanisms. Mechanical nerve irritation of entrapped nerves is likely the leading mechanism of pain while connection to striated muscle, edema and foreign body reaction appear to contribute into the development of pain. Polypropylene used in mesh manufacturing degrades while exposed to the body environment and the clinical impact of polypropylene degradation needs to be studied further. Overall, the explant specimens, mostly neglected over the decades contain primary information of the mesh-body interactions. A systematic examination reveled previously unreported findings which can help understanding of the mechanisms of complications and guide technical and treatment strategies.
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Primary Pseudomyogenic Hemangioendothelioma of Bone Alero Inyang, Carrie Inwards, Andrew Folpe, G Petur Nielsen, Andrew Rosenberg. University of Miami, Miami, FL; Mayo Clinic, Rochester, MN; Massachusetts General Hospital, Boston, MA. Background: Pseudomyogenic hemangioendothelioma (PMH) also known as "epithelioid-sarcoma-like hemangioendothelioma", is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in approximately 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 6 such cases; the largest series reported to date. Design: Cases were identified from the authors' institutions. Clinical history, imaging studies, histology, and immunohistochemistry were reviewed. Microscopically, the tumors were analyzed for growth pattern, nuclear atypia, mitoses, necrosis, and inflammatory cells. Results: The patients included 5 males and 1 female; age ranging from 14 to 74 (mean 40.5 years). Five patients had numerous multifocal lesions; 3 had disease in bones of the distal lower extremity, 1 had lesions in bones of the distal upper extremity, and 1 had tumor in the spine, ribs, scapula, pelvis, and proximal femur. The 6th patient had a solitary pelvic lesion. On X-ray and CT the tumors were well circumscribed and lytic, and some had a sclerotic rim. On MR the lesions were T2 hyper-intense. The tumors were intracortical and intramedullary cavity and limited to the skeletal system. Histologically, 5 of 6 tumors were composed predominantly of spindled cells arranged in intersecting fascicles with scattered epithelioid cells. In the sixth case the cells were mainly epithelioid. The neoplastic cells contained abundant densely eosinophilic cytoplasm, and oval to elongate vesicular nuclei, with variably distinct nucleoli. There was limited cytologic atypia, no necrosis, and few mitoses (0-2/10HPF). Tumor associated inflammation included lymphocytes, neutrophils, eosinophils, and hemosiderin-laden macrophages. The stroma was inconspicuous. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically the tumor cells were positive for keratin in all cases, ERG and CD31 in 5 of 6 cases, and FLI-1 in 2 of 3 cases; CD34 was negative. Follow-up is limited but no patient has developed metastases; and all have stable osseous disease. Conclusions: PMH exclusively involving bone is rare. It tends to be multicentric, involve the distal lower extremity, has relatively indolent radiologic features, and infrequently metastasizes or rapidly enlarges. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging. George Jour, Lu Wang, Wen Chen, John Healey, Lisa Choi, Khedoudja Nafa, Meera Hameed. Memorial Sloan Kettering Cancer Center, New York, NY. Background: Extraskeletal osteosarcoma (ESOSA) is a rare soft tissue neoplasm representing < 5% of osteosarcomas and <1% of all soft-tissue sarcomas. These tumors show osteoid and/or chondroid matrix and overlapping features with their skeletal osteosarcomas. Herein, we investigate the clinicopathological and molecular features of ESOSA in a series of cases and explore potential morphological and molecular parameters that may affect outcome. Design: 27 cases were retrieved and reviewed. Clinical history and followup were obtained through electronic record review. DNA from FFPE tissue was extracted and processed from 9 cases. DNA copy number alterations (CNA) and allelic imbalances (AI) were analyzed by SNP-array using Affymetrix OncoScan FFPE Assay using OncoScan Console (Affymetrix) and OncoScan Nexus Express software (BioDiscovery). Log rank and Cox proportional hazards models were used for statistic analysis. Results: Our series includes 27 patients [male =9, female =18] with an average age of 63 years (19-93) and a median follow up of 24 months (6-120 months). Tumor morphology included giant cell rich (n=7), undifferentiated pleomorphic sarcoma with osteoid (n=9), osteoblastic and/or chondroblastic (n=10) and telangiectatic (n=1). Tumor sites included (trunk) (n=10) and extremities (n=17). Ten patients (37%) died of their disease. Twelve (44%) showed no evidence of disease while 5 (19%) showed Background: SWI/SNF chromatin remodeling complex utilizes the energy of ATP hybrolysis to remodel nucleosomes and to modulate transcription. This complex is composed of evolutionarily conserved core subunits: SMARCB1 (INI1), SMARCA4 (BRG1), SMARCC1 (BAF155) and SMARCA2 (BAF170). These genes have the potential of tumor suppressors and these alterations have been identified in various neoplasms. Malignant rhabdoid tumor (MRT) and epithelioid sarcoma (ES) are classified as tumor of uncertain differentiation, and they show a complete loss of INI1 protein expression as well as very aggressive biological behavior. The histological features of ES, especially proximal-type ES (P-ES) resemble those of MRT. Some data regarding the histologic and immunohistochemical differences between P-ES and MRT exist, but such findings are not yet conclusive. To date, there has been no investigation focused on SWI/SNF chromatin remodeling complex in INI1-deficient tumor series. Design: We analyzed the BRG1, BAF155 and BAF170 protein expression in 34 MRTs, 20 P-ES and 28 conventional-type ES (C-ES), and these mRNA expressions in 18 MRTs (including 3 cell lines), 3 P-ESs (including 2 cell lines) and 1 C-ES cell line. A total immunostaining score was calculated as the product of a proportion score and an intensity score. The proportion score described the estimated fraction of positivestained tumor cells (0, none; 1, < 1%; 2, 1%-10%; 3, 10%-33.3%; 4, 33.3-66.7%; 5, > 66.7%). The intensity score represented the estimated staining intensity (0, no staining; 1, weak; 2, moderate; 3, strong). 
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local recurrence and/or metastasis at last follow up. Patients with tumor size > 5 cm and non-giant cell histology had a worse disease free survival (DFS) by univariate analysis (p=0.05 and p=0.03, respectively). Multivariate analysis including age, sex, site, tumor size, resection margin status, treatment modality and histological subtype didn't reveal any
Conclusions:
In MRT and ES, expressions of some core subunits of SWI/SNF chromatin remodeling complex are reduced. Therefore, combined reduced expressions of these proteins may have an important role in tumorigenesis in these tumors. In addition, evaluation of BAF155 immunoexpression may be a useful diagnostic tool to distinguish MRT from P-ES.
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Clinicopathological Prognostic Factors of Primary Central Chondrosarcoma: Analysis of 182 Cases By Numerical Score on Histology Eiichi Konishi, Yasuaki Nakashima, Masayuki Mano, Yasuhiko Tomita, Akio Yanagisawa. Kyoto Prefectural University of Medicine, Kyoto, Japan; Kyoto University Hospital, Kyoto, Japan; Osaka National Hospital, Osaka, Japan; Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan. Background: Histological diagnosis of primary central chondrosarcoma (pcCHS) is still challenging because it is unclear which features are important as objective prognostic indicators. In this study, we analyzed clinicopathological features of pcCHS, using numerical score on histology, in order to elucidate the features predicting prognosis. Clinicopathological characteristics of pCHS were also shown. Design: PcCHSs were collected within the Kansai Musculoskeletal Oncology Group, Japan. Histology of all cases were reviewed and given the numerical score on 17 pathological findings. With data of age, sex, location, follow-up period and outcome, statistical analysis was performed. Results: 182 pcCHSs were reviewed (male:female=84:98). All patients are Japanese. The average age at the presentation was 50.9 years (15-83 years). The average followup period was 65.4 months (1-258 months). 106 cases (58.2%) were of long bones, 38 (20.9%) of the bones of the limb girdles, and 6 (3.3%) of small bones of hands and feet. 30 cases (16.5%) were of the bones of the trunk and 2 (1.1%) from the skull. 21 patients died of disease. Histologically, 91 cases (50.0%) were grade 1, 71 (39.0%) were grade 2, and 20 (11.0%) were grade 3, respectively. The 5-year and 10-year disease specific survival rates were 98.7:95.1% (grade 1), 84.5:71.7% (grade 2), and 33.1:33.1% (grade 3). Survival curves of each grade were statistically different each other (p<0.05). Cox hazards analysis on the score of clinicopathological findings showed that grade, calcification and age were significant factors (p<0.05), predicting prognosis. The hazard ratios of age, grade 1 vs 2, and grade 1 vs 3 were 1.040, 5.118 and 17.914, respectively. But that of calcification was 0.176. Conclusions: By analysis of 184 pcCHSs, age and histological grade were significant predictive factors for poor prognosis (patient's death) but calcification was that for good prognosis. Calcification has been regarded as a sign of enchondroma, but it will be a simple maker for good prognosis. In Japan, there was a mild female preponderance for pcCHS. Long bones were more frequently involved than the previous results. But the prognosis was basically similar. Background: Over 90% necrosis after neoadjuvant chemotherapy is a good prognostic factor in osteosarcomas. In a recent study using tissue microarrays of 40 conventional osteosarcomas, P16 expression is shown to independently predict the necrotic response to neoadjuvant chemotherapy. In this study, we aimed to investigate this recent finding using whole sections in a larger group of osteosarcomas. Design: Eighty four cases having both pretreatment biopsies and resection specimens after neoadjuvant chemotherapy were collected from the archives of 3 reference hospitals. Age, sex, tumor size, tumor subtype, and location were recorded. Percentage of pathologic tumor necrosis was reevaluated. Four mm-thick slides of pretreatment biopsies were immunostained for P16 (BD Pharmingen, G175-405, 1:25) using Leica Bond Autostainer. Over %30 strong nuclear staining is regarded as positive. Results: Median age of the patients was 17 (range 5-68), and male to female ratio was 2.23. Mean tumor diameter was 9.9 cm (range, 2-30 cm). Tumors were most commonly of osteoblastic type (60%), followed by chondroblastic (19%) and fibroblastic (15%) subtypes. The most common locations were femur (46%), tibia (27%), and humerus (7%). P16 positivity was seen in 55% of the patients. Median percentage of pathologic necrosis was 65%; 38% of the patients gave favourable (≥90%) response to neoadjuvant therapy. In univariant analysis, P16 expression was significantly correlated with presence of ≥90% necrotic response to neoadjuvant chemotherapy (p=0.043). P16 expression was also associated with tumor size (correlation coefficient: 0.27, p=0.020), whereas patient age showed an indirect correlation with necrotic response (correlation coefficient: -0.27, p=0.013). On multivariant logistic regression analysis including age, sex, tumor subtype, location, size, and P16 expression, P16 expression (odds: 4.69, p=0.015), female sex (odds: 6.29, p=0.008) and tumor size (odds: 0.85, p=0.018) were found to be independenly associated with chemotherapy response. Conclusions: With a larger series using whole sections, P16 expression, female sex, and tumor size were found to be independent predictors of response to neoadjuvant chemotherapy in osteosarcomas.
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Angiosarcomas of the Breast: Clinicopathologic Analysis and Prognostic Features
Lik Hang Lee, Doha Itani, Laura Chin-Lenn, Ashwini Yenamandra, Tori Leftwich, Hua Yang. University of Calgary, Calgary, AB, Canada; Vanderbilt University, Nashville, TN. Background: Breast angiosarcoma is a rare condition arising de novo or secondary to breast carcinoma radiation therapy. We attempt to identify prognostic elements of breast angiosarcoma and assess MYC amplification status. Design: Cases of breast angiosarcoma diagnosed between 1997 and 2014 in our metropolitan region were selected for histopathological review and clinical data collection. A tissue microarray was established to assess MYC amplification by FISH. Results: Sixteen patients (two primary, patients 1 and 2, and fourteen secondary) were identified (Table 1) . Primary angiosarcoma occurred at a younger age (44±17 years) than secondary (69±11 years, p=0.01). Perineural invasion predicted poor disease-specific survival (DSS, p=0.03) but not disease-free survival (DFS, p=0.09). Other variables that adversely affected DSS and DFS, but showed no statistical significance, included high grade cytology, high FNCLCC grade, epithelioid/poorly differentiated growth pattern, necrosis, hemorrhage, lymphovascular invasion, and breast parenchymal involvement. All secondary angiosarcoma showed MYC amplification while primary angiosarcomas did not. Patient 1 developed a second angiosarcoma with higher grade in the opposite breast after 55 months. Conclusions: Several clinicopathologic factors appear to be relevant to patient prognosis, particularly perineural invasion. Because of the rarity of breast angiosarcomas, this case series may contribute to the knowledge on this disease.
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Multi-Platform Mutation Analysis of Gastrointestinal Stromal Tumor and Histologic-Clinical Correlation Jacqueline Lekostaj, Sarah Hornberg, Mohammed Milhem, Aaron Bossler, Deqin Ma.
University of Iowa Hospitals and Clinics, Iowa City, IA. Background: KIT and PDGFRA are the most commonly mutated genes in gastrointestinal stromal tumor (GIST). Mutations in these two genes are mutually exclusive and correlate with tumor location, aggressiveness and response to targeted therapy. We analyzed GISTs through traditional Sanger and next generation sequencing (NGS), with a focus on the clinicopathologic correlation of tumors with KIT double mutations or PDGFRA mutations. Design: Twenty-one GISTs were selected from archives. DNA sequencing of KIT and PDGFRA was performed through a combination of NGS using the Ion PGM and the AmpliSeq™ Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, CA), a laboratory developed NGS panel, and Sanger sequencing (KIT exons 8, 9, 11, 13, 15, 17). All NGS positive findings were confirmed by Sanger. The clinical course was retrieved from chart review. Results: 81% (17/21) of cases contained KIT (14) or PDGFRA (3) mutation and 2 wildtype patients carried a clinical diagnosis of neurofibromatosis 1. KIT mutations were most frequent in exon 11 (9) followed by double mutations (3) and exon 9 (2). All PDGFRA mutations were in exon 18. All patients with single KIT mutation, except 1 with W557_K558del, responded well to tyrosine kinase inhibitors (TKI). One patient with double primary KIT exon 11 and 13 mutations showed stable disease; the other had unknown mutation chronology and progressed despite multiple TKIs. The third double-mutant tumor developed a secondary mutation in exon 14 rendering it resistant to TKI. One patient with PDGFRA point mutation progressed on TKI; the other had a low-risk tumor, successfully treated with surgery. The patient with PDGFRA deletion received TKI with good outcome. 
Conclusions:
KIT double mutations and PDGFRA mutations are common in our cohort of patients and can be reliably detected by NGS. Response to TKI therapy corresponded to histology, tumor stage, and the type of mutation present.
Impact of Tissue Decalcification on Immunohistochemical Detection of Select Sarcoma Markers
Haiyan Liu, Jianhui Shi, Vivian Xu, Fan Lin. Geisinger Medical Center, Danville, PA. Background: Application of an immunohistochemical (IHC) assay on decalcified tissues is frequently performed in an anatomic pathology laboratory. It has been documented that tissue decalcification (decal) may have a negative impact on an assay for certain antigens. In this study, we investigated the impact of decal on the detection of frequently used sarcoma markers using sarcoma cell lines. Design: Three sarcoma cell lines were obtained from the American Type Culture Collection. A set of IHC markers as listed in the Table were tested on each cell line on a cell block. No single cell line expressed all markers. Three cell lines collectively expressed all target markers. The cell pellets containing a mixture of the 3 cell lines were first fixed in 10% neutral buffered formalin for 8 hours (h) and then decalcified in Decalcifier B (Fisher Healthcare, item #23245683) for the following durations: 0 minutes (min) (no decal), 30 min, 60 min, 3 h, 6 h, 1 day, 3 days and 1 week. A tissue microarray (TMA) block containing these tissue/cell line cores with the different decal times was constructed. The aforementioned IHC markers were applied to the TMA sections using the Ventana Ultra staining platform. The staining intensity was recorded as strong (S) Conclusions: These data demonstrate that tissue decal has 1) a significant negative impact on ERG detection; on myogenin, MyoD1, NKX2.2, andFli-1 detection; and on SMA detection after 30 min, 60 min, and 3 h of decal, respectively; 2) has a limited impact on the detection of desmin and CD99 following 1 week's decal.
Histologic and Immunohistochemical Analysis of Cases of Synovial Chondromatosis With Pre-Operative Concern for Malignancy Based on Radiologic Evidence of Extra-Articular Disease
Seth Lummus, Jeffrey Schowinsky. University of Colorado School of Medicine, Aurora, CO. Background: Primary synovial chondromatosis (SC) is an uncommon condition involving a proliferation of cartilage within synovium and articular spaces. While SC is regarded as a benign condition, it is reported to rarely transform to chondrosarcoma, with a recent publication suggesting such transformation may occur in up to 6% of cases. SC is usually limited to the joint space, but extra-articular spread of SC can occur, and radiologic detection of such spread is clinically worrisome for transformation to sarcoma. Recent literature suggests that 50-70% of central chondrosarcomas and enchondromas harbor mutations of IDH1 encoding isocitrate dehydrogenase 1, with R132C, R132G, and R132H mutations being most frequent. Such mutations have not previously been detected in SC. Design: A database search identified pathology cases at our hospital from 2000-2014 with a diagnosis of 'synovial chondromatosis.' Chart review was performed to identify cases with a pre-operative concern for malignancy based on extra-articular spread of disease. These cases were pulled for histologic review, and blocks selected for immunohistochemistry (IHC) with a monoclonal antibody directed against the R132H mutant form of IDH1 (Dianova, Hamburg). Results: 15 cases of synovial chondromatosis were identified, with pre-operative concern for malignancy due to extra-articular disease in 5 cases (representing 3 patients).
Review of all 5 cases showed benign appearing histology, characterized by numerous, well-separated nodules of cartilage with no significant atypia, no necrosis, and no significant mitotic activity. SC was present within the extra-synovial fibroadipose tissue in all 3 patients, and was present involving the marrow space in 1 patient. IHC showed expression of mutated IDH1 in 1 of 3 patients. Conclusions: Distinguishing between SC and chondrosarcoma in cases of locally aggressive SC poses a diagnostic difficulty for the pathologist. The literature is inconsistent in providing guidance on this subject, with some authors requiring malignant histologic features for a diagnosis of sarcoma but others not. Despite the small sample size, this study shows that locally aggressive cases of SC with entirely benign histology may express mutated IDH1 protein, which has not been reported in previous studies, further confusing the diagnostic picture. Adoption of a diagnostic categorization that recognizes this degree of diagnostic uncertainty may be prudent until more definitive diagnostic criteria are available to the pathologist. Stacey Mardekian, Bryan Hozack, John Abraham, Brian O'Hara, Atrayee BasuMallick, Wei Jiang. Thomas Jefferson University, Philadelphia, PA. Background: Chordoma is a rare but locally aggressive malignancy. We aimed to identify risk factors associated with local recurrence, which may help guide clinical surveillance and treatment decisions. Design: We performed a retrospective study of 60 patients diagnosed with chordoma between 1990 and 2014, who underwent surgery in our institution. Medical charts and all available pathology cases (n=94) were reviewed. Clinical and histologic variables were recorded. Descriptive statistic analyses (Student t tests, Fisher exact probability tests, and Mann-Whitney's U tests) were performed (2-tailed for all). p values <0.05 were considered statistically signifi-cant. Results: In the entire cohort (n=60), the mean age at presentation was 56.4 yrs (19-83); M:F=1.3:1, and 89% were Caucasians (Black 7%, Asian 4%). Tumor size averaged 5.2 cm (range 1.6-15.0). Radiation therapy was given to 47.4% of patients. Local recurrence rate was 68% (n=38), and four patients had recurrence twice. The average time between primary tumor and the first recurrence was 51.4 months (range 7-122, n=12), and 30.5 months between the first and the second recurrence (range 14-52, n=4). Four patients had metastasis (7.2%, n=55) (all to local/distant soft tissue and/or dermis). One patient had primary clivus tumor, then developed C2-3 lesion, and later, C5 lesion, which may be either metastasis or multifocal primary disease. Among all the clinical and histologic factors, the only statistically significant variable associated with local recurrence was the presence of tumor heterogeneity (p=0.03) (see Table 1 ). Margin status was difficult to evaluate since in many cases the specimen was received as aggregates (n=6 for non-recurrence group, n=15 for recurrence group). Patients without local recurrence had much better overall survival than patients with recurrence (124.2 vs. 65.6 months, p=0.012).
Assessment for Risk Factors Associated With Local Recurrence in Chordoma
Conclusions:
Our study is one of the largest clinicopathologic series of chordoma from a single institution, with long-term follow up data. The high rate of local recurrence seemed to dictate the clinical outcome, and our finding of histologic heterogeneity associated with local recurrence was quite interesting. Larger studies are needed to validate the result, which may influence the clinical management. Kim Mayhall, Eleanor Lewin, Helena Lebeau, Tong Wu, Byron Crawford. Tulane University Medical School, New Orleans, LA. Background: Leiomyosarcoma (LMS) is a malignant smooth muscle tumor. Expression of novel antibody smoothelin has previously been evaluated in gastrointestinal (GI) smooth muscle tumors but has yet to be studied in LMS of uterine and other soft tissue origin. DOG-1 expression is reported to be specific for GIST tumors. However, there is variable expression in LMS reported depending on site of origin. Overexpression of p16 is common in LMS of uterine and other types but has not been evaulated by tumor grade. This study explores the differential expression of these markers, in addition to caldesmon, in LMS cases to assess diagnostic utility. Design: Using tissue microarrays, expression of smoothelin, DOG-1, caldesmon and p16 was evaluated by immunohistochemistry in 80 cases of LMS. The casese were subdivided by location of origin into uterine (N=30), non-uterine (N=50) and GI (N=10), as well as by grade into low grade (N=26) and intermediate and high grade (N=53). Differential expression among different grades and locations was evaluated. Smoothelin was also assessed in 20 benign uterine leiomyomas.
Evaluation of Immunohistochemical Markers Smoothelin, DOG-1, Caldesmon and p16 in Leiomyosarcomas of Different Grades and Anatomical Sites of Origin
Results:
The results of our study are shown.
Low Grade LMS
Smoothelin DOG1
Caldesmon p16
Uterine (N=9) 1/9 (11%) 0/9 4/9 (44%) 5/9 (56%) Center Komagome Hospital, Tokyo, Japan; National Cancer Center Central Hospital, Tokyo, Japan. Background: Fibroma of tendon sheath is a benign fibrous tumor typically involving the acral sites. In addition to its classic histology, it may occasionally display hypercellular fasciitis-like growth pattern (FTS-f), which closely resembles nodular fasciitis (NF). Similar histologic appearance and the association with antecedent trauma in a subset of both entities may suggest oncogenic relationship between NF and FTS-f. Because most NFs have recently been shown to have recurrent MYH6-USP6 fusion genes, we seek to investigate FTS-f cases for the status of each of these partner gene by using chromogenic in situ hybridization (CISH) to determine the genetic relationship between NF and FTS-f. Design: Formalin-fixed paraffin-embedded specimens of 11 NFs, 1 intravascular fasciitis (IF) and 7 FTS-fs were retrieved. FTS-fs comprised fasciitis-like area in 5-80% of the tumor (mean, 40%). Three deep benign fibrous histiocytomas (BFH) were used as negative controls. All the specimens were subjected to CISH analysis using customdesigned dual-color break-apart MYH9 and USP6 probes and DAKO Duo CISH. Rearrangement-positive nuclei were scored by counting 100 lesional spindle cells. Results: All NFs harbored USP6 rearrangement in 6-30% (mean, 17%) of the cells. All but 1 (10/11, 91%) NF also showed MYH9 rearrangement in 6-32% (mean, 16%) of the cells, indicating MYH9-USP6. As a negative control, the 3 BFHs lacked MYH9 and USP6 rearrangements with a positive-cell ratio of 1-2% (mean, 1.3%) and 0-2% (mean, 1.3%), respectively. All 7 FTS-fs and 1 IF lacked MYH9 and USP6 gene rearrangements with a positive-cell ratio being 0-2% (mean, 0.9%) and 0-3% (mean, 1.1%) in FTS-fs, respectively, and 1% and 0% in IF, respectively. Conclusions: Despite histological similarity, FTS-f lacks USP6 rearrangements and is cytogenetically distinct from NF. Consistent with prior reports, the USP6 gene rearrangements were successfully demonstrated in all NFs. However, the rearrangements were found only in a subset of their lesional cells, which may reflect intratumoral heterogeneity of these "transient neoplasms". This modest positive-cell ratio in NFs may also represent a potential diagnostic pitfall, and it highlights the usefulness of CISH assays that enable bright-field visualization of cellular morphology. been developed to overcome the practical limitations of FISH and IHC. In this study, we evaluate the diagnostic utility of this novel assay to distinguish secondary AS from other cutaneous vascular proliferations. Design: Formalin-fixed, paraffin-embedded blocks from 12 secondary AS, 5 atypical vascular lesions (AVL), 3 primary AS, 2 chronic lymphedema, 2 angiomatosis/capillary hemangioma, and 1 congenital vascular malformation were retrieved from our surgical pathology archives and examined by DISH, using a commercially available probe. Appropriate controls were employed. Results: 11/12 secondary AS showed MYC gene amplification (10 cases with > 8 MYC/CHR8 ratio and 1 case with ≥ 2 MYC/CHR8 ratio). Polysomy of chromosome 8 was present in one secondary AS (3 to 5 copies of MYC and CHR8). All cases of AVL, primary AS, chronic lymphedema, angiomatosis/hemangioma, and vascular malformation did not demonstrate MYC gene amplification or chromosomal aberration. Conclusions: Based on our results, the determination of the MYC gene status using this fully automated DISH assay is a reliable technique and has many advantages. DISH could be a reasonable alternative to IHC and FISH in distinguishing secondary AS from AVL and other cutaneous vascular proliferations.
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Diagnostic Utility of TGFBI To Distinguish Chondrosarcoma From Enchondroma Hany Osman, Howard Wu, Shaoxiong Chen. Indiana University School of Medicine, Indianapolis, IN. Background: Low grade chondrosarcoma (CHS) and enchondroma pose a significant diagnostic challenge due to overlapping morphological features. To this date, there have not been reliable markers reported to distinguish chondrosarcoma from other cartilaginous tumors. Liquid chromatography -tandem mass spectrometry (LC-MS/ MS) was carried out to identify possible diagnostic markers. In the present study, we evaluate the utility of TGFBI immunostaining in distinguishing CHS (grade I and II) from enchondroma. Design: Protein extracts from formalin-fixed paraffin-embedded tissue blocks of low grade chondrosarcoma (5 cases) and enchondroma (5 cases) were analyzed using LC-MS/MS, and TGFBI was identified as a potential candidate marker for CHS. TGFBI was validated by studying its expression in 31 CHS (25 grade I and 6 grade II) and 36 enchondromas immunohistochemically. Only extracellular staining within the tumor matrix was considered positive. The immunostaining of TGFBI was scored according to percentage of staining in the whole tumor area (0,<5%; 1+, 5-25%; 2+, 26-50%; 3+, 51-100%) and intensity (weak, moderate, or strong). Results: Among the 31 chondrosarcoma cases, 13 cases (9 grade I and 4 grade II) were positive for TGFBI (3+ in 6 cases, 2+ in 2 cases, 1+ in 5 cases), while only 4 out of the 36 enchondromas were positive (2+ in 1 cases, 1+ in 3 cases). Retrospective review of the H&E slides of 4 enchondroma cases with positive TGFBI staining showed one case displayed morphological features consistent with CHS. Majority of the positive cases showed strong intensity of staining. Conclusions: TGFBI, a secreted extracellular matrix protein (ECM), is found increased in various tumors and can promote tumor metastasis. Immunostaining for TGFBI expression has a high specificity (89%) and moderate sensitivity (42%) for CHS and can be useful in differentiating chondrosarcoma from enchondroma. The impact of TGFBI on prognosis is yet to be studied. Janne Rand, Kai Wang, Christine Sheehan, Tipu Nazeer, Siraj Ali, Julia Elvin, Roman Yelensky, Doron Lipson, Juliann Chmielecki, Vincent Miller, Philip Stephens, Jeffrey Ross. Albany Medical College, Albany, NY; Foundation Medicine Inc, Cambridge, MA. Background: Bone chordomas are rare slow-growing malignant bone tumors arising from fetal notochord, usually within vertebral bodies. Chordomas represent 1% of primary malignant bone tumors. Thiry-seven % of chordomas metastasize to other organs and 5% undergo dedifferentiation which may be present at the time of diagnosis. Aggressive surgery is generally needed to treat chordoma. The mean survival is approximately 7 years. We queried whether bone chordomas featured clinically relevant genomic alterations that could lead to targeted therapies for patients with either unresectable primary tumors or metastatic disease. Design: DNA was extracted from 40 microns of FFPE sections from 38 samples of clinically advanced chordomas. Comprehensive genomic profiling was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 618X for 3,230 exons of 182 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The results were evaluated for all classes of genomic alterations (GA). Clinically relevant genomic alterations were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials. Results: There were 18 male and 21 female patients with a mean age of 52.6. Three (7.9%) showed chondroid differentiation, two (5.3%) were dedifferentiated, thirty-three (86.8%) showed conventional histology. There were eight (21%) stage III, and thirty (79%) stage IV tumors at the time profiling. A total of 61 GA were identified (1.6 GA/ chordoma) in 35 genes. Twenty (53%) of the chordomas featured at least 1 clinically relevant alteration. The most frequent altered genes were PI3K/mTOR pathway. Nine (24%) of the samples harbored alterations in this pathway, including PTEN (10.5%), AKT3 (2.6%), MTOR (2.6%), PIK3CA (2.6%), TSC2 (2.6%), and STK11 (2.6%). Other clincally meaningful alterations were identified including alterations in CCND1, CDK4, ERBB3, IGF1R and PTCH1. Conclusions: Bone chordomas are rare malignant neoplasms that require aggressive surgery for treatment. For patients with clinically advanced disease genomic profiling can uncover potential targets for systemic therapy. The resulting wide array of potential targeted therapies both on the market and in clinical trials mandates that comprehensive diagnostic approaches be used to maximize treatment options for patients with this aggressive form of malignancy.
Comprehensive Genomic Profiling of Bone Chordomas Reveals High Frequency of mTOR Pathway Alterations and Potential New Routes To Targeted Therapies
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Cytogenomic Microarray Analysis of Dedifferentiated Liposarcoma: A Molecular Study in Search of Potential Biomarkers Robert Ricciotti, George Jour, Benjamin Hoch, Yajuan Liu. University of Washington, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY. Background: Molecular abnormalities underlying the pathogenesis and behavior of dedifferentiated liposarcoma (DDLS) are not well understood. Tumor location and FNCLCC grade of DDLS have been shown to have prognostic significance. CDK4 amplification and copy number alterations (CNA) of other specific chromosomal loci have been proposed as having prognostic value; however, the significance of these and other potential biomarkers has not been fully elucidated. Design: Thirty DDLS were retrieved and reviewed by a bone and soft tissue pathologist. Clinical information was obtained through electronic record review. DNA from FFPE tumor tissue was extracted and analyzed by cytogenomic microarray analysis. Data analysis was performed using Cytogenomics 2.7 to identify CNAs and level of amplification for CDK4 and MDM2. Results: CNAs in 6 regions of interest were compared with DDLS grade and disease status (mean follow-up 29 months). All cases with 19q13.11 loss (n=4) showed disease progression (DP) defined as local recurrence, metastasis, or death, and all with 19q13.11 gain (n=3) had no evidence of disease (NED) at last follow-up (Fisher's exact test p=0.0286). Three cases with 19q13.11 loss were grade 3 and all with gain were grade 1-2 tumors (p=0.1429). Five of 6 cases with CNAs of 3q29 (4 loss, 1 gain) had DP at last follow-up, including one with distant metastasis. This difference did not reach statistical significance. CNAs of 3q29 did not correlate with grade. Loss of 9p22.1 (n=11) and/or 11q24.2 (n=11) did not correlate with disease progression or grade. CDK4 was amplified in 29 cases (range 10 to 72 copies). Level of CDK4 amplification tended to be higher in cases with DP. All cases with very high levels of amplification (>39 copies, n=5), showed DP, but this trend did not achieve statistical significance (Wilcoxon rank-sum test p=0.26). MDM2 amplification did not correlate with grade or disease progression.
Conclusions:
The finding of 19q13.11 gain has not been previously described in DDLS. 19q13.11 loss and gain significantly correlate with worse and better outcome, respectively, but not with grade. In contrast to what has been previously reported CNAs at 3q29 may be more common in cases with DP, including metastasis, and 9p22.1 abnormality did not correlate with DP. High levels of CDK4 amplification tend to be found in DDLS with DP as previously reported. Analysis of larger numbers of cases and identification of candidate genes are required to further define molecular biomarkers in DDLS. The morphological interpretation sometimes can be challenging due to overlapping features, especially between epithelioid haemangiomas (EH) and epithelioid haemangioendotheliomas (EHE). Recently, translocations have been reported to occur in classic EHE (WWTR1-CAMTA1), EHE with vasoformative architecture and a better prognosis (YAP1-TFE3), and EH with atypical features (ZFP36-FOSB), but not yet in conventional EH. These translocations may provide tools to differentiate between these two types of tumors with different therapeutic and prognostic implications. The aim of this study was to evaluate the use of TFE3 immunohistochemistry and FISH in the differential diagnosis of epithelioid vascular lesions. Design: TFE3 overexpression was evaluated by immunohistochemistry in 21 EH and 12 EHE from the archives of 6 bone and soft tissue tumour referral centers. In the subgroup of tumors with high TFE3 expression (4 EH + 2 EHE), FISH for TFE3 was performed. Results: Seven out of 21 EH (33%) and five out of 12 EHE (41%) demonstrated strong positive TFE3 nuclear immunostaining. There were no clear histological differences between TFE3+ and TFE3-EH or EHE. Only 2 out of 4 TFE3+ EH and none out of 2 TFE3+ EHE showed rearrangement of the TFE3 gene by FISH. In retrospect, the 2 cases diagnosed as EH carrying TFE3 rearrangement demonstrated some hybrid features between EH and EHE. Both patients were free of disease with a follow up of 13 and 36 months respectively. Conclusions: TFE3 positive immunostaining is not indicative of the presence of a TFE3 rearrangement in epithelioid vascular lesions. We here report on the occurrence of TFE3 rearrangement in 2 lesions previously diagnosed as EH, that had in retrospect some areas reminiscent of EHE, supporting previous claims that TFE3 rearranged epithelioid vascular tumors define a separate entity with a better outcome as compared to classic EHE. Salvatore Romeo, Sabrina Rossi, Fabio Canal, Marta Sbaraglia, Licia Laurino, Guido Mazzoleni, Maria Montesco, Laura Valori, Marta Campo Dell'Orto, Andrea Gianatti, Alexander Lazar, Angelo Dei Tos. Treviso General Hospital, Treviso, Italy; Bolzano Regional Hospital, Bolzano, Italy; Istituto Oncologico Veneto, Padova, Italy; Ospedali Riuniti di Bergamo, Bergamo, Italy; University of Texas MD Anderson Cancer Center, Houston, TX. Background: Recently a few cases of synovial sarcoma (SS) of the abdominal viscera have been reported, raising awareness about the potential for confusion between this entity and KIT-negative gastrointestinal stromal tumors (GIST). We report the clinicopathological, immunophenotypical and molecular features of fifteen more SS occurring in the stomach (8 cases), epigastric region (one case), small intestine (one cases), large intestine (three cases), involving both the terminal ileum and the caecum (one case) and liver (one case). Design: Patients' clinical records were retrieved. Haematoxilin Eosin slides were reviewed and immunostains for SMA, DESMIN, CD34, CD117, S100, EMA, CK AE1/3, TLE1, CD56, CD99, BCL2, DOG1 were performed. Rearrengement of SS18 gene region was screened in all cases: by conventional karyotype in one case and by either interphase FISH or Q-PCR or both in the remaining cases. Results: Ten patients were male and five female, with an age range of 17-61 years (median 44). Tumour size ranged from 2 to 15 cm (median 8). Mitoses per 10 HPF ranged from 4 to 27 (median 9.5). Eleven tumours were monophasic fibrous SS, one biphasic SS and three poorly differentiated SS. SMA, Desmin, CD34, CD117 and S100 were negative in all cases, whereas EMA and/or CK AE1/AE3 were positive in all cases. TLE1, BCL2 and CD56 were positive in all tested cases. DOG1 was positive in one case. SS18 gene region rearrangement was demonstrated in all cases. A fusion transcript was amplified in eight cases: either syt-ssx1 or syt-ssx2 respectively in four cases each. Follow-up information was available for 11 patients : range from 6 to 185 months ( 47 median). Conclusions: SS is increasingly recognized at visceral sites. Molecular analyses play a key role when dealing with usual histotypes in unusual sites. Correct diagnosis is crucial for appropriate therapy.
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TFE3 Expression and Rearrangement in Epithelioid Vascular
Primary Synovial Sarcoma (SS) of the Digestive System: A Molecular and Clinicopathological Study of Fifteen Cases
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Predictors of Recurrence in Giant Cell Tumor of Bone Lauren Rosen, Diana Murro, Paolo Gattuso. Rush University Medical Center, Chicago, IL. Background: Giant Cell Tumor of Bone (GCTB) is a benign but potentially aggressive tumor with a high rate of local recurrence and a low risk of distant metastases. Radiographic and histologic grading systems do not accurately predict clinical course. Our goal is to determine if a group of immunohistochemical (IHC) markers can serve as predictors of clinically aggressive behavior. Design: Institutional surgical pathology records were searched from January 1993-June 2014 for cases of GCTB. Primary cases were stratified into recurrent (PR) and nonrecurrent (PNR) groups. Clinical data including age, sex, tumor site, treatment and time to recurrence was collected. For cases in which paraffin blocks were available, IHC stains for Ki67, p63, p53, cyclin-D1, and c-myc were performed. Slides were reviewed blindly and independently by 2 pathologists. Ki67 was scored as low-intermediate (0-20%), and high (≥ 21%). Of the remaining stains, ≥ 5% tumor cell staining was considered positive, and intensity was scored as low (1-2+) or high (3+). Pearson chi-squared test was used for data analysis. Results: 85 cases of GCTB were identified, including 22(25%) with recurrence and 3(4%) with lung metastases. Patients had a mean age of 37 years at diagnosis, with a male to female ratio of 1.4:1. Tumors were most commonly located in the distal femur and proximal tibia (42% of cases). Primary tumors were treated either by curettage (71%) or resection (29%). Among the recurrent cases, 15 had 1 recurrence, 6 had 2 recurrences, and 1 had 4. Mean time to first recurrence was 17 months. Recurrences occurred in 17/59 (28%) of patients treated with curettage and 5/30 (20%) of patients treated with resection. Paraffin blocks were available for staining in 9 PNR and 18 PR tumors. Cyclin D1 was preferentially expressed in the nuclei of giant cells, while the other stains were expressed predominately by mononuclear cells. There was no significant difference between clinical variables among the PR and PNR groups. The proportion of patients older than 45 was higher in the PNR group (p=0.067). P63 staining intensity was significantly higher in PR group (p=0.044). Conclusions: Of the IHC stains studied, only p63 staining intensity was found to be of value in distinguishing recurrent from non-recurrent GCTB (p=0.044). Patients older than 45 are less likely to experience recurrence than younger patients (p=0.067). Interestingly, type of surgical procedure did not correlate with risk of recurrence. 
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The Wnt Receptor ROR2 Is a Novel Prognostic Marker and Potential Therapeutic Target in Dedifferentiated Liposarcoma Navid Sadri, M Celeste Simon. Memorial Sloan Kettering Cancer Center, New York, NY; University of Pennsylvania School of Medicine, Philadelphia, PA. Background: Genetically defined by chromosome 12q13-15 amplification, welldifferentiated liposarcoma (WD-LPS) and dedifferentiated liposarcoma (DD-LPS) constitute a spectrum of disease, from an indolent low-grade, lipogenic tumor (WD-LPS) to a highly aggressive non-lipogenic (DD-LPS) tumor with metastatic potential. The molecular and cellular events underlying dedifferentiation are poorly understood. Wnt signaling is suggested to play an important role in both adipogenesis and sarcoma pathobiology. Design: To determine the role of Wnt signaling in liposarcoma dedifferentiation, we compared the expression of Wnt receptors in WD-LPS and DD-LPS samples using available human datasets, which revealed an increase in ROR2 in DD-LPS. To explore the requirement of ROR2 in liposarcoma pathogenesis, we performed knockdown experiments using two independent shRNAs in DD-LPS cell lines. We examined the effects of ROR2 expression in vivo using a xenotransplantation model of DD-LPS. To identify downstream targets of ROR2 we used correlation expression studies using publicly available DD-LPS datasets and confirmed predicted correlations by qRT-PCR and western blot analysis. Results: The expression of ROR2 strongly correlates with worse overall survival in patients with WD/DD-LPS. Silencing of ROR2 expression in WD-LPS and DD-LPS cell lines significantly inhibits tumor growth, induces PPARγ expression (master regulator of adipogenesis), and promotes adipogenic differentiation. Mechanistically, we propose that ROR2 expression inhibits adipogenic differentiation through repression of PPARγ by modulating upstream AP-1 transcription factors, FosL2 and c-Fos.
Conclusions:
The up-regulation of ROR2 has previously been reported in osteosarcoma, leiomyosarcoma and GIST. Here we propose upregulation of ROR2 in DD-LPS represses PPARγ expression and adipogenic differentiation through the differential regulation of AP-1 factors. ROR2 may serve as a prognostic and potential therapeutic target in DD-LPS. 5-24.5cm(median, 7.8cm) . Tumors involved the femur(n=13), chest wall(n=6), pelvic girdle(n=4), vertebrae(n=3), humerus(n=2), tibia(n=1), and fibula(n=1). Radiographic information and imaging was available in all cases. Of cases occurring in long bones, 70% were epiphyseal; 15% located at non-epiphyseal locations; and 15% were unable to be localized due to large tumor size and bone destruction. Tumors were typically circumscribed by a rim of sclerotic bone. Histologically, CCC consisted predominantly of round cells with clear to eosinophilic cytoplasm. Cases additionally possessed areas of metaplastic woven bone(90%), intralesional osteoid deposition(66%), and multinucleated osteoclast giant cells(33%). Cases of CCC expressed S-100 protein(66%), CD99(66%), and pancytokeratin(50%). Patients often presented with pathologic fracture, localized to regionalized pain, and often of long duration. No patients had metastases at the time of diagnosis. Six patients died of disease after 15 to 201mo(median, 97mo); 7 patients were alive with disease and 13 without evidence of disease(median, 51mo). Metastases developed in 4 patients after periods of up to 64mo. Recurrences occurred in 11 patients. Histologic differences, mitotic activity, and tumor size were not related to CCC behavior or patient survival. Cases of CCC had better overall survival than Grade 2 and 3 chondrosarcoma control groups (p<0.05). Conclusions: Clear cell chondrosarcoma is rare and can often be misdiagnosed; its range of morphologic, immunophenotypic, and behavioral differences separates it from its radiographic and histologic mimics. When compared to historical controls of conventional chondrosarcoma(Grade 2 and 3), CCC appeared to follow a less aggressive clinical course. Background: NCOA2 encodes a protein that assists nuclear hormone receptors in transcription activation. Recently, NCOA2 was discovered to be involved in a recurrent translocation t(8;8)(q13.3;q21.1) in mesenchymal chondrosarcomas (MChs), which results in the fusion of HEY1 with NCOA2 and subsequent NCOA2 overexpression. MChs is a rare malignant biphasic cartilaginous tumor composed of primitive mesenchymal cells and islands of well-differentiated hyaline cartilage, of which either component can be mistaken for other small round cell and cartilaginous tumors, especially on small biopsies. We examined the diagnostic utility of NCOA2 immunohistochemical study in mesenchymal chondrosarcomas as well as its expression in other bone and soft tissue mesenchymal tumors, some of which may resemble MChs. Design: 100 whole and tissue microarray formalin-fixed paraffin-embedded sections were examined consisting of 26 MChs, 10 Ewing sarcoma(ES), 7 synovial sarcoma(SS), 22 solitary fibrous tumors(SFT), 15 leiomyosarcoma(LM), 8 chondrosarcomas(Chs), 8 osteosarcomas(OS), 2 enchondroma(En), 1 myxoid liposarcoma(Mlps) and 1 extraskeletal myxoid chondrosarcoma(EMC). Immunohistochemistry using an anti-NCOA2 antibody (AbCam, 1:200) was performed on 5mm-thick paraffin embedded sections. Labeling was assessed for both degree (weak, moderate, strong) and extent (0; 1+, <5%; 2+, 5-25%; 3+, 26-50%; 4+, 51-75%; 5+, >75%). 2+ nuclear labeling of any extent was considered to be positive. Results: 24/26 MChs were positive for NCOA2 overexpression, with at least 2+ labeling, most with strong/moderate labeling. Other tumors also positive for NCOA2 included: 8/8 OS (majority 5+, strong), 10/10 SFT (5+, at least moderate), 13/15 LMS (5+, at least moderate), 7/8 Chs (majority 2-3+, moderate), 1/1 EMC, 1/1 MLPs. 6 of 10 ES (most with at least 4+, moderate) and 1/7 SS labeled for NCOA2. None of the En labeled for NCOA2. Conclusions: NCOA2 nuclear expression is characteristic of mesenchymal chondrosarcoma. However, it is also expressed in other mesenchymal tumors, including mimickers of MChs and could pay a role in tumorigenesis of these entities. Thus, molecular testing (on-going) is recommended to differentiate MChs from potential mimics.
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Symplastic/Pseudoanaplastic Giant Cell Tumor of the Bone Judy Sarungbam, Narasimhan Agaram, Sinchun Hwang, Chao Lu, John Healey, Meera Hameed. Memorial Sloan Kettering Cancer Center, New York, NY; Rockefeller University, New York, NY. Background: Giant cell tumor of bone (GCTB) is a locally aggressive benign primary bone tumor comprising of mononuclear cells associated with evenly distributed numerous multinucleated osteoclast-like giant cells. The malignant counterpart of this tumor, primary malignant GCTB is quite rare and is characterized by sarcomatous transformation in a "de novo" GCTB or a secondary recurrent phenomenon from a previous conventional or radiated GCTB. Rarely conventional GCTB shows marked nuclear atypia referred to as symplastic/pseudoanaplastic change, which can mimic sarcomatous transformation. Herein we report a series of 8 cases of GCTB with symplastic /pseudoanaplastic change. Design: A total of 181 cases of GCTB were identified from the pathology database of a tertiary care cancer center from 1993 to 2011. Eight cases of GCTB with symplastic change were identified and pathology slides of these cases were reviewed. Electronic medical records were reviewed for imaging features and clinical follow-ups. Ki 67 immunohistochemical analysis was performed on all 8 cases of GCTB with symplastic change. Sequencing of H3F3A gene is in process on all of the 8 cases.
Results: The 8 cases of GCTB with symplastic change included 6 females and 2 males, median age of 43.9years (range:28 -64 years). Anatomic locations included distal femur (2), vertebra (3), proximal tibia (1), fibula (1) and ischium (1). Imaging features were concordant with GCTB including eccentrically located, expansile lytic lesions with cortical involvement. Histologic examination showed giant cells distributed in a uniform manner with interspersed mononuclear cells, whose nuclei have similar morphological appearance to the nuclei of giant cells. In all cases, mononuclear cells showed scattered foci of marked nuclear pleomorphism, with enlarged hyperchromatic nuclei, smudged nuclear chromatin and nuclear pseudoinclusions. Mitotic figures were not seen in these cells. While overall Ki-67 proliferative index ranged from 0-10%, these atypical and pleomorphic cells did not label with Ki-67. One patient (ischium) had radiation therapy and denosumab treatment and showed treatment associated exuberant new bone formation in curetted material. Clinical follow-up ranged from 10 to 196 months (median:70 months). Local recurrence was seen in 4 cases (50%). Conclusions: GCTB with symplastic/pseudoanalplastic change is an uncommon variant of conventional GCTB which can mimic sarcomatous transformation. The relative absence of Ki-67 staining in these atypical cells can be useful in distinguishing it from malignant GCTB.
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Malignant Peripheral Nerve Sheath Tumor (MPNST) Arising in Diffuse-Type Neurofibroma Inga-Marie Schaefer, Christopher Fletcher. Brigham & Women's Hospital, Boston, MA. Background: Diffuse-type neurofibroma is an uncommon variant of neurofibroma, associated with neurofibromatosis type 1 (NF-1) in ∼60% of cases. Typically presenting in young adults as ill-defined plaque-like dermal/subcutaneous thickening, most cases are located on the trunk or head and neck region. Malignant transformation is extremely rare. Design: Eight cases of MPNST arising in diffuse-type neurofibroma were identified in consult files between 1994 and 2014. H&E and immunohistochemical stains were examined. Clinical and follow-up information was obtained from referring pathologists and clinicians. Results: Five patients were male and 3 female, aged between 31 and 59 years (median, 47.5 years). The diffuse-type neurofibromas were ill-defined subcutaneous lesions with diffuse growth pattern and infiltration between adnexal structures and adipose tissue, with tumor size ranging from 3.6 to 45 cm (median, 15 cm). All contained Meissner corpuscles. Four patients (#1-4) had a clinical history of NF-1, and one patient (#5) had Klippel-Trénaunay-Weber syndrome. 6/8 tumors arose on the trunk, and one tumor each on the leg and scalp, respectively. Areas of increased cellularity, nuclear atypia, increased nuclear-cytoplasmic ratio, and scattered mitoses (range, 1-63/50 HPF) were observed in all tumors, indicating transition to MPNST which was classified as low grade in 5 cases, intermediate to high grade in one case, and high grade in 2 cases, of which one showed heterologous angiosarcomatous differentiation. The neurofibroma components expressed S-100 quite strongly, whereas the areas of MPNST showed expression levels ranging from weak to moderate. Staining with neurofilament protein revealed scattered axons in one case (#6). Follow-up data, available for all cases (median, 80.5 months), revealed that one patient (#3) developed local recurrence after 9 months, treated with re-excision. One patient (#5) had pulmonary metastases at initial diagnosis and died one month after tumor resection. All other patients were alive and without evidence of disease after 15-145 months (median, 83 months). Conclusions: Diffuse-type neurofibroma may show transformation to MPNST in very rare instances, highlighted by focal hypercellularity, nuclear atypia, and mitoses. It is important to be aware of possible malignant transformation in diffuse-type neurofibroma, requiring thorough sampling of resection specimens and long-term clinical-follow-up of patients with unexcised lesions.
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The Since that time, NELL-1 has been found to induce significant ossification in both small and large animal models of bone repair. With this, new molecular data suggests that NELL-1 induces bone formation by binding to IntegrinB1 and activating Wnt/Bcatenin signaling. Despite this, expression of NELL-1 in benign and malignant bone tumors is entirely unknown. Design: Human specimens were obtained from the UCLA pathology database (N=5-10 specimens per diagnosis). Tumor types included osteoid osteoma, osteoblastoma, osteosarcoma (OS) (osteoblastic, fibroblastic, and chondroblastic types), parosteal OS, periosteal OS, and telangiectatic OS. Demographics, history of chemotherapy and radiation, and clinical course were recorded. NELL-1 expression was documented via antibodies to either the C-or N-terminus. Semi-quantitative assessment of NELL-1 immunohistochemical staining was performed, documenting the presence, intensity, and distribution of immunostaining. Spatial correlation with osteogenic markers (Bone Sialoprotein, BSP; Osteocalcin, OCN) and Wnt signaling activity was performed (Axin2). Results: NELL-1 expression was present in all bone tumors. Among benign bone tumors, strong and diffuse staining was observed across all tumors. This diffuse expression of NELL-1 correlated with osteogenic marker expression (OCN, BSP) and diffuse Wnt signaling activity (Axin2). In contrast, a relative reduction in NELL-1 staining and increased variability between tumor specimens was observed within OS. Surprisingly, among OS subtypes, fibroblastic osteosarcoma demonstrated the most reliable expression of NELL-1. Among OS, NELL-1 expression did not correlate with markers of osteogenesis (OCN, BSP) nor Wnt signaling activity.
Conclusions:
Reliable and diffuse NELL-1 expression is a characteristic feature of osteoid osteoma and osteoblastoma. In contrast, NELL-1 expression is reduced in intensity and distribution in OS. NELL-1 expression in benign bone tumors is associated with osteogenic marker expression and Wnt signaling activity. Future studies will further examine the diagnostic, prognostic and basic biologic importance of NELL-1 in bone tumors.
ATRX Loss Is a Poor Prognostic Factor in Extrauterine Leiomyosarcomas
Aatur Singhi, Rohit Bhargava, Miroslawa W Jones, Kristi Cressman, Raja Seethala. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: Leiomyosarcomas (LMS) are rare malignant tumors of smooth muscle origin and associated with a poor long-term prognosis. However, the clinical course of these tumors is not entirely predictable using conventional prognostic parameters, which do not take into account the biopsy of these neoplasms. Recent studies have identified activation of alternative lengthening of telomeres (ALT) in over 50% of LMS. ALT is a telomere maintenance mechanism and results in immortal growth of tumor cells. In addition, the ALT phenotype is associated with loss of ATRX protein expression, but the status of ATRX has not been fully characterized in LMS. Thus, immunohistochemical staining for ATRX was performed on a large cohort of LMS and correlated with various clinicopathologic factors. Design: 108 surgically resected LMS (63 extrauterine and 45 uterine LMS) were immunolabeled for ATRX. Cases were scored as ATRX-negative in the absence of nuclear staining within neoplastic cells, while retained within surrounding nonneoplastic parenchyma. Results were correlated with patient demographics, pathologic features, disease-free survival (DFS) and disease-specific survival (DSS). The follow-up period ranged from 0.3 to 19 years (mean, 3.9 yrs; median, 3 yrs). Results: ATRX loss was identified in 42 of 108 (39%) LMS with 5 cases demonstrating intratumoral heterogeneity. No significant differences between ATRX status and patient sex (p = 0.50), mean tumor size (p = 0.46), uterine vs extrauterine location (p = 0.23), tumor differentiation (p = 0.06), FNCLCC grade (p = 0.39) and vascular invasion (p = 0.18) were observed. However, ATRX-negative extrauterine LMS did correlate with shorter mean DFS (0.8 vs 3.6 yrs, p < 0.001) and shorter mean DSS (2.8 vs 14.8 yrs, p < 0.001); while, among uterine LMS, no differences in mean DFS or DSS were seen with regards to ATRX status (p > 0.05).
Conclusions:
Loss of ATRX is a poor prognostic factor and associated with disease recurrence and decreased survival in patients with extrauterine LMS after surgical resection. In contrast, ATRX status seems to be irrelevant in uterine LMS, suggesting biologic differences between uterine and extrauterine LMS.
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Evaluation of ETV1 Expression in Gastrointestinal Stromal Tumors (GIST) By Chromogenic RNA In Situ Hybridization Steven Smith, Nallasivam Palanisamy, Jonathan McHugh, David Lucas, Brian Rubin, Rajiv Patel. Virginia Commonwealth University Health System, Richmond, VA; University of Michigan, Ann Arbor, MI; Cleveland Clinic, Cleveland, OH. Background: Several lines of evidence implicate a key role for the ETS-family transcription factor, ETV1, in GIST, with computational studies implicating ETV1-dependent transcription as central to GIST molecular pathogenesis. However, due to the marked sequence homology between ETS family members and lack of specific antibodies for immunohistochemistry, evaluation of ETV1 expression in situ in archival tissues has proved very challenging, limiting interpretation (let alone, diagnostic utility) of ETV1 immunostains. Design: A tissue microarray of 49 GISTs from varying primary sites in the gastrointestinal tract was stained by chromogenic RNA in situ hybridization (ISH) for ETV1. ETV1 expression was evaluated by intensity and proportion (0-4+) using a RNA ISH scoring system, recently validated in prostate cancer. Distributions of scores were compared with clinicopathologic and morphologic parameters by non-parametric correlation and chi square tests. Results: All GISTs evaluated showed at least focal, low intensity expression of ETV1, including 29% with 1+, 50% 2+, and 21% 3+ expression; higher intensities such as seen in prostatic adenocarcinomas harboring ETV1 translocation were not observed. ETV1 ISH scores were not significantly associated with GIST tumor size, risk stratum, mutational status/type, or immunohistochemical expression of KIT. ETV1 ISH scores trended toward lesser intensity of expression in gastric versus non-gastric GISTs (p=0.055), reflective of the significantly lesser intensity of ETV1 ISH scores in epithelioid GISTs versus GISTs with spindled cytomorphology (p=0.001).
Conclusions:
We provide the first specific demonstration of ETV1 expression in archival tissues of GISTs through use of chromogenic ISH. These findings establish a new, specific reagent for the study of ETV1 expression patterns in situ and identify an intriguing pattern of differential expression intensity between epithelioid and spindle cell GISTs.
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Molecular Analysis of the Ras-Raf-MAPK Pathway in Langerhans Cell Histiocytosis David Solomon, Nancy Joseph, James Grenert, Andrew Horvai. University of California, San Francisco, CA. Background: Langerhans cell histiocytosis (LCH) is an aggressive neoplasm of Langerhans cells that commonly arises in the skeleton and hypothalamus of children and young adults. Approximately 50% of LCH cases harbor BRAF-V600E mutations, and response to therapy with the BRAF inhibitor vemurafenib has been reported. Recent studies have identified other genetic alterations in the Ras-Raf-MAPK signaling pathway in LCH cases without BRAF mutation. Determination of the genetic alterations that drive LCH will improve diagnostic methods for histiocytic neoplasms and direct targeted therapy for this disease. Design: Genomic DNA was purified from formalin-fixed, paraffin-embedded cases of LCH from 51 patients retrieved from the UCSF pathology archives. PCR-based melting curve analysis over exon 15 of the BRAF gene was performed. Sanger sequencing of KRAS, NRAS, and MAP2K1 genes and assessment for BRAF rearrangement by intronic next-generation sequencing is being performed. Molecular findings are being correlated with clinicopathologic data from the patient cohort. Results: BRAF mutations were identified in 17/34 cases presenting with unifocal disease (50%), 8/14 cases presenting with multifocal disease (57%), and 1/3 cases of disease limited to pulmonary involvement (33%). No significant correlation of BRAF-V600 mutation status with patient age, sex, site of disease presentation, or disease recurrence after therapy was identified. The results of KRAS, NRAS, and MAP2K1 sequencing as well as testing for BRAF rearrangement in this cohort is underway and will be presented. Conclusions: These studies are delineating the molecular pathways that define LCH and will direct future clinical trials of targeted therapeutics for LCH using BRAF and MEK inhibitors based on the unique molecular alterations present in each patient's tumor.
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Novel Background: The molecular characterization of SBRCTs is still evolving due to the rapid advancement of next generation sequencing, in particular paired-end RNA sequencing which is highly sensitive for novel translocation discovery. About two-thirds of EWSR1-negative SBRCTs are associated with CIC-DUX4 related fusions, while another small subset with BCOR-CCNB3 X-chromosomal paracentric inversions. In this study we sought to characterize further a large cohort of SBRCTs negative for previously reported gene abnormalities. Design: We applied next generation paired-end RNA sequencing and FusionSeq algorithm to an intra-abdominal SBRCT index case from a 44 year-old man. The results identified the presence of a BCOR-MAML3 fusion, in keeping with a t(x;4)(p11;q31) translocation, which was then confirmed by RT-PCR and was associated with marked up-regulation of MAML3. FISH using custom BAC probes for BCOR, MAML3 and ZC3H7B, a previously reported partner of BCOR, was applied in a large cohort of 72 SBRCTs which were negative for EWSR1, FUS, and CIC rearrangements. Results: FISH studies revealed the typical BCOR-CCNB3 inversion in 6/72 (8%) cases tested, with an additional subset of 9/72 (13%) tumors showing a distinctive BCOR break-apart pattern, without CCNB3 abnormalities. This last subset occurred all except one in males, with a mean age of 36 years (range 5-70), mostly in soft tissue (5/9) and 2 each in bone and lung. Among the BCOR-rearranged SBRCTs, 2 cases showed MAML3 fusions (index case and iliac bone), with ZC3H7B in an additional soft tissue tumor. Conclusions: This molecular study further expands the genetic signature of SBRCTs, with two additional novel fusions BCOR-MAML3 and BCOR-ZC3H7B being identified in EWSR1 and CIC-negative tumors. RT-PCR for BCOR-CCNB3 fusions or CCNB3 IHC will not be appropriate for detecting these alternative fusions, which will be identified instead by FISH technique. MAML3 and ZC3H7B have been previously implicated in other translocation-associated mesenchymal lesions, such as biphenotypic sinonasal sarcoma and ossifying fibromyxoid tumor/endometrial stromal sarcoma, respectively. Background: FDC sarcomas are rare neoplasms with a low to intermediate malignant potential that may be diagnostically challenging due to their rarity and variable histologic patterns. This study aims to further characterize the morphologic spectrum, IHC features, and biologic behavior of this tumor in the largest series of cases to date. Design: Ninety-eight cases of FDC sarcomas were retrieved. The morphologic, IHC, and ultrastructural features and outcome data were analyzed. Results: The patients were 54F and 44M ranging from 14-88 yrs(median 51 yrs). The tumors ranged in size from 1.0-30.0 cm(median 7.9 cm), and were primary nodal in 30/98(30%) of cases. The anatomic distribution was as follows: head and neck(n=26), thorax(n=33), abdomen(n=37), and extremities(n=2). Fifty percent(50%) of patients had multicentric disease. Histologically, tumors were comprised of fascicles and storiform arrays of oval to spindle cells with vesicular chromatin, distinct nucleoli, and indistinct cytoplasmic borders forming frequent whorls. Electron microscopy performed on selected cases revealed the presence of abundant desmosomes and well-formed cellular junctions. By IHC, 55/56(98%) cases were positive for clusterin, 28/32(88%) for fascin, 12/14(86%) for EGFR, 74/93(80%) for CD21, 54/87(62%) for CD35, and 37/63(59%) for CD23. Follow-up data was available in 42/98 of patients; 31% of patients were found to have metastatic disease at time of presentation, and 42% of patients had disease recurrence after surgery. The median time to recurrence was 9 mo(range: 1-106 mo). Fifty-five percent(55%) died of disease 3 to 188 mo after diagnosis(median survival 21 mo). The 3-and 5-yr survival rates were 71% and 55%, respectively. Survival outcomes
